| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | protein serine/threonine kinase activity | CDK16 CDK18 LMTK2 ALPK1 CHUK CASK NUAK2 SGK2 PHKA1 CAMKK2 CSNK1A1L NUAK1 CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 1.17e-13 | 446 | 103 | 20 | GO:0004674 |
| GeneOntologyMolecularFunction | protein serine kinase activity | CDK16 CDK18 LMTK2 ALPK1 CASK NUAK2 SGK2 CAMKK2 CSNK1A1L NUAK1 CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 4.16e-13 | 363 | 103 | 18 | GO:0106310 |
| GeneOntologyMolecularFunction | protein kinase activity | CDK16 CDK18 SRC LMTK2 ALPK1 CHUK CASK NUAK2 SGK2 PHKA1 CAMKK2 CSNK1A1L NUAK1 CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 3.13e-12 | 600 | 103 | 21 | GO:0004672 |
| GeneOntologyMolecularFunction | phosphotransferase activity, alcohol group as acceptor | CDK16 CDK18 SRC LMTK2 ALPK1 CHUK CASK NUAK2 SGK2 PHKA1 CAMKK2 CSNK1A1L NUAK1 PIK3C2B CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 9.40e-12 | 709 | 103 | 22 | GO:0016773 |
| GeneOntologyMolecularFunction | kinase activity | CDK16 CDK18 SRC LMTK2 ALPK1 CHUK CASK NUAK2 SGK2 PHKA1 CAMKK2 CSNK1A1L NUAK1 PIK3C2B CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 4.00e-11 | 764 | 103 | 22 | GO:0016301 |
| GeneOntologyMolecularFunction | transferase activity, transferring phosphorus-containing groups | CDK16 CDK18 NMNAT1 SRC LMTK2 ALPK1 CHUK CASK NUAK2 SGK2 PHKA1 CAMKK2 CSNK1A1L NUAK1 PIK3C2B CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 3.23e-10 | 938 | 103 | 23 | GO:0016772 |
| GeneOntologyMolecularFunction | cyclin-dependent protein serine/threonine kinase activity | 8.73e-09 | 30 | 103 | 6 | GO:0004693 | |
| GeneOntologyMolecularFunction | cyclin-dependent protein kinase activity | 8.73e-09 | 30 | 103 | 6 | GO:0097472 | |
| GeneOntologyMolecularFunction | phospholipid binding | ESYT1 ANXA6 DAB1 DAB2 APOB CPS1 ESYT2 ABCG1 PIK3C2B AKT1 VDAC1 | 1.23e-04 | 548 | 103 | 11 | GO:0005543 |
| GeneOntologyMolecularFunction | endopolyphosphatase activity | 2.61e-04 | 5 | 103 | 2 | GO:0000298 | |
| GeneOntologyMolecularFunction | ATP:ADP antiporter activity | 2.61e-04 | 5 | 103 | 2 | GO:0005471 | |
| GeneOntologyMolecularFunction | bis(5'-adenosyl)-hexaphosphatase activity | 2.61e-04 | 5 | 103 | 2 | GO:0034431 | |
| GeneOntologyMolecularFunction | diphosphoinositol-polyphosphate diphosphatase activity | 2.61e-04 | 5 | 103 | 2 | GO:0008486 | |
| GeneOntologyMolecularFunction | protein kinase C binding | 3.76e-04 | 66 | 103 | 4 | GO:0005080 | |
| GeneOntologyMolecularFunction | bis(5'-adenosyl)-pentaphosphatase activity | 3.90e-04 | 6 | 103 | 2 | GO:0034432 | |
| GeneOntologyMolecularFunction | histone kinase activity | 3.98e-04 | 28 | 103 | 3 | GO:0035173 | |
| GeneOntologyMolecularFunction | ephrin receptor binding | 5.93e-04 | 32 | 103 | 3 | GO:0046875 | |
| GeneOntologyMolecularFunction | phosphatidylcholine binding | 7.10e-04 | 34 | 103 | 3 | GO:0031210 | |
| GeneOntologyMolecularFunction | cyclin binding | 7.74e-04 | 35 | 103 | 3 | GO:0030332 | |
| GeneOntologyMolecularFunction | cell adhesion molecule binding | 1.06e-03 | 599 | 103 | 10 | GO:0050839 | |
| GeneOntologyMolecularFunction | ADP transmembrane transporter activity | 1.41e-03 | 11 | 103 | 2 | GO:0015217 | |
| GeneOntologyMolecularFunction | quaternary ammonium group binding | 1.72e-03 | 46 | 103 | 3 | GO:0050997 | |
| GeneOntologyMolecularFunction | magnesium ion binding | 1.77e-03 | 247 | 103 | 6 | GO:0000287 | |
| GeneOntologyMolecularFunction | 4 iron, 4 sulfur cluster binding | 1.83e-03 | 47 | 103 | 3 | GO:0051539 | |
| GeneOntologyMolecularFunction | cadherin binding | 1.88e-03 | 339 | 103 | 7 | GO:0045296 | |
| GeneOntologyMolecularFunction | L-arginine transmembrane transporter activity | 1.98e-03 | 13 | 103 | 2 | GO:0061459 | |
| GeneOntologyMolecularFunction | ATP transmembrane transporter activity | 2.30e-03 | 14 | 103 | 2 | GO:0005347 | |
| GeneOntologyMolecularFunction | transporter activity | SLC31A2 ESYT1 SLC38A4 ANXA6 APOB SLCO1B7 SLCO5A1 ABCG1 NALCN ABCA6 SLC25A2 NIPA2 SLC25A31 VDAC1 SLC35B1 | 2.48e-03 | 1289 | 103 | 15 | GO:0005215 |
| GeneOntologyBiologicalProcess | peptidyl-serine phosphorylation | LMTK2 CHUK SGK2 CSNK1A1L CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK5 | 3.56e-07 | 307 | 102 | 11 | GO:0018105 |
| GeneOntologyBiologicalProcess | peptidyl-serine modification | LMTK2 CHUK SGK2 CSNK1A1L CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK5 | 5.20e-07 | 319 | 102 | 11 | GO:0018209 |
| GeneOntologyBiologicalProcess | negative regulation of cellular component organization | FLNA ITGB1BP1 SRC DAB1 DAB2 APC DCC THOC2 LDLR PTPN13 CSNK1A1L CSNK1A1 DYNC1LI1 AKT1 SLC25A31 CDK5 | 5.08e-06 | 864 | 102 | 16 | GO:0051129 |
| GeneOntologyBiologicalProcess | vesicle-mediated transport between endosomal compartments | 8.38e-06 | 56 | 102 | 5 | GO:0098927 | |
| GeneOntologyBiologicalProcess | regulation of catabolic process | CDK16 FLNA NMNAT1 SRC DAB2 APC IREB2 LDLR PHKA1 CAMKK2 NOD1 CSNK1A1L SF3B3 TIMP2 CSNK1A1 AKT1 VDAC1 CDK2 CDK5 | 1.07e-05 | 1252 | 102 | 19 | GO:0009894 |
| GeneOntologyBiologicalProcess | regulation of protein catabolic process | 3.40e-05 | 407 | 102 | 10 | GO:0042176 | |
| GeneOntologyBiologicalProcess | cell division | BRIP1 ITGB1BP1 APC THOC2 LIG3 CSNK1A1L CSNK1A1 MASTL DYNC1LI1 CDK1 CDK2 CDK3 CDK5 | 3.95e-05 | 697 | 102 | 13 | GO:0051301 |
| GeneOntologyBiologicalProcess | cytoplasmic pattern recognition receptor signaling pathway | 4.16e-05 | 188 | 102 | 7 | GO:0002753 | |
| GeneOntologyBiologicalProcess | DNA damage response | BRIP1 APC TIPRL LIG3 SF3B3 NUAK1 FANCI RAD54B MASTL AKT1 CDK1 CDK2 CDK3 CDK5 VCPIP1 | 7.27e-05 | 959 | 102 | 15 | GO:0006974 |
| GeneOntologyBiologicalProcess | organophosphate catabolic process | 7.79e-05 | 281 | 102 | 8 | GO:0046434 | |
| GeneOntologyBiologicalProcess | cellular response to oxygen-containing compound | CDK16 FLNA NRIP1 BRIP1 SRC APC IREB2 CPS1 ADCY2 LDLR CHUK ABCG1 FAT1 CAMKK2 NOD1 AKT1 CDK1 CDK2 CDK5 | 8.01e-05 | 1450 | 102 | 19 | GO:1901701 |
| GeneOntologyBiologicalProcess | pattern recognition receptor signaling pathway | 1.07e-04 | 294 | 102 | 8 | GO:0002221 | |
| GeneOntologyBiologicalProcess | early endosome to late endosome transport | 1.09e-04 | 50 | 102 | 4 | GO:0045022 | |
| GeneOntologyBiologicalProcess | lipid localization | NRIP1 ESYT1 DAB2 APOB FASLG LDLR SLCO1B7 ESYT2 ABCG1 ABCA6 AKT1 | 1.11e-04 | 565 | 102 | 11 | GO:0010876 |
| GeneOntologyBiologicalProcess | cellular catabolic process | CDK16 SRC APOB CPS1 LDLR PHKA1 CAMKK2 NOD1 EFNB1 GLA TIMP2 PIK3C2B AKT1 PLCB3 HAGH VDAC1 CDK5 | 1.32e-04 | 1253 | 102 | 17 | GO:0044248 |
| GeneOntologyBiologicalProcess | negative regulation of calcium import into the mitochondrion | 1.44e-04 | 4 | 102 | 2 | GO:0110099 | |
| GeneOntologyBiologicalProcess | organophosphate metabolic process | DPYD NMNAT1 SRC AGPAT4 GMPR2 CPS1 ADCY2 LDLR CASK NUDT11 LPCAT2 PIK3C2B NUDT10 PLCB3 ENO2 VDAC1 | 1.48e-04 | 1142 | 102 | 16 | GO:0019637 |
| GeneOntologyBiologicalProcess | maintenance of location | 1.54e-04 | 396 | 102 | 9 | GO:0051235 | |
| GeneOntologyBiologicalProcess | organophosphate ester transport | 1.55e-04 | 162 | 102 | 6 | GO:0015748 | |
| GeneOntologyBiologicalProcess | negative regulation of cell projection organization | 1.59e-04 | 233 | 102 | 7 | GO:0031345 | |
| GeneOntologyBiologicalProcess | innate immune response-activating signaling pathway | 1.60e-04 | 312 | 102 | 8 | GO:0002758 | |
| GeneOntologyBiologicalProcess | positive regulation of TORC1 signaling | 1.70e-04 | 56 | 102 | 4 | GO:1904263 | |
| GeneOntologyBiologicalProcess | positive regulation of catabolic process | CDK16 SRC DAB2 APC LDLR PHKA1 CAMKK2 NOD1 CSNK1A1L CSNK1A1 AKT1 VDAC1 | 1.78e-04 | 701 | 102 | 12 | GO:0009896 |
| GeneOntologyBiologicalProcess | regulation of integrin-mediated signaling pathway | 1.94e-04 | 23 | 102 | 3 | GO:2001044 | |
| GeneOntologyBiologicalProcess | negative regulation of neuron projection development | 1.95e-04 | 169 | 102 | 6 | GO:0010977 | |
| GeneOntologyBiologicalProcess | positive regulation of intracellular signal transduction | FLNA NMNAT1 ITGB1BP1 SRC DAB2 ZNF622 ALPK1 DCC ATAT1 FASLG CHUK NOD1 CSNK1A1L TIMP2 CSNK1A1 DYNC1LI1 AKT1 | 2.03e-04 | 1299 | 102 | 17 | GO:1902533 |
| GeneOntologyBiologicalProcess | lipid transport | 2.05e-04 | 506 | 102 | 10 | GO:0006869 | |
| GeneOntologyBiologicalProcess | adenosine 5'-(hexahydrogen pentaphosphate) metabolic process | 2.40e-04 | 5 | 102 | 2 | GO:1901910 | |
| GeneOntologyBiologicalProcess | adenosine 5'-(hexahydrogen pentaphosphate) catabolic process | 2.40e-04 | 5 | 102 | 2 | GO:1901911 | |
| GeneOntologyBiologicalProcess | diadenosine pentaphosphate catabolic process | 2.40e-04 | 5 | 102 | 2 | GO:1901907 | |
| GeneOntologyBiologicalProcess | diadenosine pentaphosphate metabolic process | 2.40e-04 | 5 | 102 | 2 | GO:1901906 | |
| GeneOntologyBiologicalProcess | diadenosine hexaphosphate catabolic process | 2.40e-04 | 5 | 102 | 2 | GO:1901909 | |
| GeneOntologyBiologicalProcess | diadenosine hexaphosphate metabolic process | 2.40e-04 | 5 | 102 | 2 | GO:1901908 | |
| GeneOntologyBiologicalProcess | diphosphoinositol polyphosphate metabolic process | 2.40e-04 | 5 | 102 | 2 | GO:0071543 | |
| GeneOntologyBiologicalProcess | cell morphogenesis | FLNA SRC DAB1 DAB2 APC LMTK2 DCC THOC2 CASK FAT1 CSNK1A1L EFNB1 CSNK1A1 AFDN KIF5C CDK5 | 2.45e-04 | 1194 | 102 | 16 | GO:0000902 |
| GeneOntologyBiologicalProcess | activation of innate immune response | 2.49e-04 | 333 | 102 | 8 | GO:0002218 | |
| GeneOntologyBiologicalProcess | ribonucleotide catabolic process | 2.58e-04 | 178 | 102 | 6 | GO:0009261 | |
| GeneOntologyBiologicalProcess | ribonucleotide metabolic process | 3.10e-04 | 533 | 102 | 10 | GO:0009259 | |
| GeneOntologyBiologicalProcess | ribose phosphate metabolic process | 3.43e-04 | 540 | 102 | 10 | GO:0019693 | |
| GeneOntologyBiologicalProcess | purine-containing compound catabolic process | 3.45e-04 | 188 | 102 | 6 | GO:0072523 | |
| GeneOntologyBiologicalProcess | diadenosine polyphosphate catabolic process | 3.59e-04 | 6 | 102 | 2 | GO:0015961 | |
| GeneOntologyBiologicalProcess | endoplasmic reticulum-plasma membrane tethering | 3.59e-04 | 6 | 102 | 2 | GO:0061817 | |
| GeneOntologyBiologicalProcess | integrin-mediated signaling pathway | 3.79e-04 | 124 | 102 | 5 | GO:0007229 | |
| GeneOntologyBiologicalProcess | regulation of nitric-oxide synthase activity | 3.91e-04 | 29 | 102 | 3 | GO:0050999 | |
| GeneOntologyBiologicalProcess | metal ion transport | FLNA SLC31A2 SLC38A4 ANXA6 LMTK2 FASLG CASK NALCN NIPA2 AKT1 PLCB3 VDAC1 CDK2 CDK5 | 4.02e-04 | 1000 | 102 | 14 | GO:0030001 |
| GeneOntologyBiologicalProcess | glycerolipid catabolic process | 4.02e-04 | 70 | 102 | 4 | GO:0046503 | |
| GeneOntologyBiologicalProcess | nucleobase-containing small molecule metabolic process | DPYD NMNAT1 SRC GMPR2 CPS1 ADCY2 CASK NUDT11 TGDS NUDT10 ENO2 VDAC1 | 4.04e-04 | 767 | 102 | 12 | GO:0055086 |
| GeneOntologyBiologicalProcess | triglyceride catabolic process | 4.33e-04 | 30 | 102 | 3 | GO:0019433 | |
| GeneOntologyBiologicalProcess | regulation of cytoplasmic pattern recognition receptor signaling pathway | 4.54e-04 | 129 | 102 | 5 | GO:0039531 | |
| GeneOntologyBiologicalProcess | response to nutrient levels | DPYD BRIP1 SRC CPS1 LDLR NUAK2 CSNK1A1L PIK3C2B CSNK1A1 AKT1 | 4.96e-04 | 566 | 102 | 10 | GO:0031667 |
| GeneOntologyBiologicalProcess | regulation of calcium import into the mitochondrion | 5.00e-04 | 7 | 102 | 2 | GO:0110097 | |
| GeneOntologyBiologicalProcess | nucleotide catabolic process | 5.90e-04 | 208 | 102 | 6 | GO:0009166 | |
| GeneOntologyBiologicalProcess | positive regulation of TOR signaling | 6.07e-04 | 78 | 102 | 4 | GO:0032008 | |
| GeneOntologyBiologicalProcess | regulation of proteasomal ubiquitin-dependent protein catabolic process | 6.38e-04 | 139 | 102 | 5 | GO:0032434 | |
| GeneOntologyBiologicalProcess | MAPK cascade | NMNAT1 ITGB1BP1 SRC DAB2 APC ZNF622 DCC C3orf33 CAMKK2 NOD1 TIMP2 AKT1 CDK1 | 6.67e-04 | 930 | 102 | 13 | GO:0000165 |
| GeneOntologyBiologicalProcess | positive regulation of proteolysis | 7.10e-04 | 390 | 102 | 8 | GO:0045862 | |
| GeneOntologyBiologicalProcess | nucleoside phosphate catabolic process | 7.19e-04 | 216 | 102 | 6 | GO:1901292 | |
| GeneOntologyBiologicalProcess | receptor metabolic process | 7.34e-04 | 82 | 102 | 4 | GO:0043112 | |
| GeneOntologyBiologicalProcess | cell cycle checkpoint signaling | 7.36e-04 | 217 | 102 | 6 | GO:0000075 | |
| GeneOntologyBiologicalProcess | positive regulation of protein metabolic process | HSPE1 ITGB1BP1 SRC DAB1 DAB2 APC FASLG LDLR ABCG1 CAMKK2 NOD1 CSNK1A1L CSNK1A1 FANCI MASTL AKT1 CDK5 | 7.69e-04 | 1458 | 102 | 17 | GO:0051247 |
| GeneOntologyBiologicalProcess | neuron development | CDK16 FLNA DAB1 DAB2 APC LMTK2 MPDZ DCC ATAT1 THOC2 CASK EFNB1 AFDN AKT1 DCLK2 KIF5C CDK5 | 7.98e-04 | 1463 | 102 | 17 | GO:0048666 |
| GeneOntologyBiologicalProcess | pallium development | 8.29e-04 | 222 | 102 | 6 | GO:0021543 | |
| GeneOntologyBiologicalProcess | positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 8.40e-04 | 85 | 102 | 4 | GO:0032436 | |
| GeneOntologyBiologicalProcess | diadenosine polyphosphate metabolic process | 8.52e-04 | 9 | 102 | 2 | GO:0015959 | |
| GeneOntologyBiologicalProcess | protein-DNA covalent cross-linking repair | 8.52e-04 | 9 | 102 | 2 | GO:0106300 | |
| GeneOntologyBiologicalProcess | regulation of cellular localization | CDK16 FLNA ITGB1BP1 SRC DAB2 APC THOC2 CASK ABCG1 AFDN AKT1 DCLK2 CDK1 CDK5 VCPIP1 | 8.90e-04 | 1212 | 102 | 15 | GO:0060341 |
| GeneOntologyBiologicalProcess | regulation of protein localization | CDK16 FLNA ITGB1BP1 SRC DAB2 APC CASK ABCG1 AFDN AKT1 DCLK2 CDK1 CDK5 VCPIP1 | 9.14e-04 | 1087 | 102 | 14 | GO:0032880 |
| GeneOntologyBiologicalProcess | calcium ion transport | 9.50e-04 | 509 | 102 | 9 | GO:0006816 | |
| GeneOntologyBiologicalProcess | positive regulation of protein catabolic process | 9.51e-04 | 228 | 102 | 6 | GO:0045732 | |
| GeneOntologyBiologicalProcess | purine ribonucleotide metabolic process | 9.90e-04 | 512 | 102 | 9 | GO:0009150 | |
| GeneOntologyBiologicalProcess | cellular response to angiotensin | 1.02e-03 | 40 | 102 | 3 | GO:1904385 | |
| GeneOntologyBiologicalProcess | peptidyl-amino acid modification | SRC LMTK2 ATAT1 CHUK SGK2 CSNK1A1L CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK5 | 1.04e-03 | 976 | 102 | 13 | GO:0018193 |
| GeneOntologyBiologicalProcess | intracellular receptor signaling pathway | 1.08e-03 | 416 | 102 | 8 | GO:0030522 | |
| GeneOntologyBiologicalProcess | neutral lipid catabolic process | 1.09e-03 | 41 | 102 | 3 | GO:0046461 | |
| GeneOntologyBiologicalProcess | acylglycerol catabolic process | 1.09e-03 | 41 | 102 | 3 | GO:0046464 | |
| GeneOntologyBiologicalProcess | negative regulation of cell junction assembly | 1.09e-03 | 41 | 102 | 3 | GO:1901889 | |
| GeneOntologyBiologicalProcess | carbohydrate derivative catabolic process | 1.12e-03 | 323 | 102 | 7 | GO:1901136 | |
| GeneOntologyBiologicalProcess | protein localization to plasma membrane | 1.14e-03 | 324 | 102 | 7 | GO:0072659 | |
| GeneOntologyBiologicalProcess | positive regulation of innate immune response | 1.14e-03 | 420 | 102 | 8 | GO:0045089 | |
| GeneOntologyBiologicalProcess | cellular response to fatty acid | 1.17e-03 | 42 | 102 | 3 | GO:0071398 | |
| GeneOntologyBiologicalProcess | regulation of proteolysis | HSPE1 SRC DAB2 FASLG NOD1 CSNK1A1L TIMP2 CSNK1A1 AKT1 CDK2 CDK5 | 1.18e-03 | 748 | 102 | 11 | GO:0030162 |
| GeneOntologyBiologicalProcess | cellular response to lipoprotein particle stimulus | 1.26e-03 | 43 | 102 | 3 | GO:0071402 | |
| GeneOntologyBiologicalProcess | regulation of NLRP3 inflammasome complex assembly | 1.26e-03 | 43 | 102 | 3 | GO:1900225 | |
| GeneOntologyBiologicalProcess | negative regulation of cell-matrix adhesion | 1.26e-03 | 43 | 102 | 3 | GO:0001953 | |
| GeneOntologyBiologicalProcess | regulation of monooxygenase activity | 1.34e-03 | 44 | 102 | 3 | GO:0032768 | |
| GeneOntologyCellularComponent | growth cone | 3.47e-06 | 245 | 103 | 9 | GO:0030426 | |
| GeneOntologyCellularComponent | site of polarized growth | 4.51e-06 | 253 | 103 | 9 | GO:0030427 | |
| GeneOntologyCellularComponent | cyclin-dependent protein kinase holoenzyme complex | 1.26e-05 | 61 | 103 | 5 | GO:0000307 | |
| GeneOntologyCellularComponent | serine/threonine protein kinase complex | 1.28e-05 | 157 | 103 | 7 | GO:1902554 | |
| GeneOntologyCellularComponent | protein kinase complex | 2.14e-05 | 170 | 103 | 7 | GO:1902911 | |
| GeneOntologyCellularComponent | anchoring junction | FLNA TES SYNM ANXA6 ITGB1BP1 SRC DAB2 APC MPDZ ATAT1 CASK FAT1 AFDN AKT1 RPL3 PDZD2 | 2.22e-05 | 976 | 103 | 16 | GO:0070161 |
| GeneOntologyCellularComponent | beta-catenin destruction complex | 3.21e-05 | 13 | 103 | 3 | GO:0030877 | |
| GeneOntologyCellularComponent | focal adhesion | 5.35e-05 | 431 | 103 | 10 | GO:0005925 | |
| GeneOntologyCellularComponent | cell-substrate junction | 6.72e-05 | 443 | 103 | 10 | GO:0030055 | |
| GeneOntologyCellularComponent | axonal growth cone | 7.09e-05 | 45 | 103 | 4 | GO:0044295 | |
| GeneOntologyCellularComponent | centrosome | DIS3L ITGB1BP1 APC ALPK1 CSNK1A1L TIMP2 CSNK1A1 MASTL DYNC1LI1 CDK1 MTUS2 CDK2 PDZD2 | 1.05e-04 | 770 | 103 | 13 | GO:0005813 |
| GeneOntologyCellularComponent | microtubule organizing center | DIS3L ITGB1BP1 APC ALPK1 CSNK1A1L TIMP2 CSNK1A1 MASTL DYNC1LI1 AKT1 CDK1 MTUS2 CDK2 PDZD2 | 1.65e-04 | 919 | 103 | 14 | GO:0005815 |
| GeneOntologyCellularComponent | transferase complex, transferring phosphorus-containing groups | 2.54e-04 | 335 | 103 | 8 | GO:0061695 | |
| GeneOntologyCellularComponent | pore complex | 2.78e-04 | 26 | 103 | 3 | GO:0046930 | |
| GeneOntologyCellularComponent | distal axon | 3.01e-04 | 435 | 103 | 9 | GO:0150034 | |
| GeneOntologyCellularComponent | somatodendritic compartment | FLNA SRC DAB1 APC LMTK2 MPDZ IREB2 APOB ADCY2 LDLR CASK TIMP2 AFDN KIF5C ENO2 CDK5 | 3.24e-04 | 1228 | 103 | 16 | GO:0036477 |
| GeneOntologyCellularComponent | mitochondrial permeability transition pore complex | 4.97e-04 | 7 | 103 | 2 | GO:0005757 | |
| GeneOntologyCellularComponent | cell body | FLNA SRC DAB1 APC LMTK2 IREB2 APOB CASK PTPN13 TIMP2 KIF5C ENO2 CDK5 | 6.41e-04 | 929 | 103 | 13 | GO:0044297 |
| GeneOntologyCellularComponent | cell-cell junction | 6.75e-04 | 591 | 103 | 10 | GO:0005911 | |
| GeneOntologyCellularComponent | neuronal cell body | FLNA SRC DAB1 APC LMTK2 IREB2 APOB CASK TIMP2 KIF5C ENO2 CDK5 | 8.31e-04 | 835 | 103 | 12 | GO:0043025 |
| GeneOntologyCellularComponent | lamellipodium | 9.78e-04 | 230 | 103 | 6 | GO:0030027 | |
| GeneOntologyCellularComponent | chromosomal region | 1.14e-03 | 421 | 103 | 8 | GO:0098687 | |
| GeneOntologyCellularComponent | axon | FLNA SRC APC LMTK2 IREB2 DCC ATAT1 TIMP2 AFDN KIF5C ENO2 CDK5 | 1.45e-03 | 891 | 103 | 12 | GO:0030424 |
| GeneOntologyCellularComponent | polymeric cytoskeletal fiber | FLNA SYNM SRC APC ATAT1 CSNK1A1L CSNK1A1 DYNC1LI1 CDK1 KIF5C MTUS2 CDK5 | 1.56e-03 | 899 | 103 | 12 | GO:0099513 |
| GeneOntologyCellularComponent | mitochondrial nucleoid | 2.04e-03 | 51 | 103 | 3 | GO:0042645 | |
| GeneOntologyCellularComponent | nucleoid | 2.04e-03 | 51 | 103 | 3 | GO:0009295 | |
| GeneOntologyCellularComponent | membrane raft | 2.11e-03 | 362 | 103 | 7 | GO:0045121 | |
| GeneOntologyCellularComponent | membrane microdomain | 2.17e-03 | 364 | 103 | 7 | GO:0098857 | |
| GeneOntologyCellularComponent | apical part of cell | 2.61e-03 | 592 | 103 | 9 | GO:0045177 | |
| GeneOntologyCellularComponent | low-density lipoprotein particle | 2.76e-03 | 16 | 103 | 2 | GO:0034362 | |
| GeneOntologyCellularComponent | condensed chromosome | 4.15e-03 | 307 | 103 | 6 | GO:0000793 | |
| HumanPheno | Uterine leiomyosarcoma | 2.55e-06 | 28 | 42 | 5 | HP:0002891 | |
| HumanPheno | Leiomyosarcoma | 2.55e-06 | 28 | 42 | 5 | HP:0100243 | |
| HumanPheno | Transitional cell carcinoma of the bladder | 4.33e-06 | 31 | 42 | 5 | HP:0006740 | |
| HumanPheno | Hereditary nonpolyposis colorectal carcinoma | 5.10e-06 | 32 | 42 | 5 | HP:0006716 | |
| HumanPheno | Bladder carcinoma | 5.97e-06 | 33 | 42 | 5 | HP:0002862 | |
| HumanPheno | Bladder neoplasm | 6.96e-06 | 34 | 42 | 5 | HP:0009725 | |
| HumanPheno | Self-injurious behavior | 3.94e-05 | 210 | 42 | 9 | HP:0100716 | |
| HumanPheno | Fibroadenoma of the breast | 4.23e-05 | 9 | 42 | 3 | HP:0010619 | |
| HumanPheno | Soft tissue sarcoma | 4.92e-05 | 166 | 42 | 8 | HP:0030448 | |
| Domain | Kinase-like_dom | CDK16 CDK18 SRC LMTK2 ALPK1 CHUK CASK NUAK2 SGK2 CAMKK2 PTPN13 CSNK1A1L NUAK1 PIK3C2B CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 2.09e-13 | 542 | 104 | 22 | IPR011009 |
| Domain | PROTEIN_KINASE_ATP | CDK16 CDK18 SRC LMTK2 CHUK CASK NUAK2 SGK2 CAMKK2 CSNK1A1L NUAK1 CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 7.97e-12 | 459 | 104 | 19 | PS00107 |
| Domain | Ser/Thr_kinase_AS | CDK16 CDK18 CHUK CASK NUAK2 SGK2 CAMKK2 CSNK1A1L NUAK1 CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 1.26e-11 | 357 | 104 | 17 | IPR008271 |
| Domain | S_TKc | CDK16 CDK18 CHUK CASK NUAK2 SGK2 CAMKK2 CSNK1A1L NUAK1 CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 1.38e-11 | 359 | 104 | 17 | SM00220 |
| Domain | PROTEIN_KINASE_ST | CDK16 CDK18 CHUK CASK NUAK2 SGK2 CAMKK2 CSNK1A1L NUAK1 CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 1.57e-11 | 362 | 104 | 17 | PS00108 |
| Domain | Prot_kinase_dom | CDK16 CDK18 SRC LMTK2 CHUK CASK NUAK2 SGK2 CAMKK2 CSNK1A1L NUAK1 CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 2.38e-11 | 489 | 104 | 19 | IPR000719 |
| Domain | PROTEIN_KINASE_DOM | CDK16 CDK18 SRC LMTK2 CHUK CASK NUAK2 SGK2 CAMKK2 CSNK1A1L NUAK1 CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 2.74e-11 | 493 | 104 | 19 | PS50011 |
| Domain | Protein_kinase_ATP_BS | CDK16 CDK18 SRC LMTK2 CHUK NUAK2 SGK2 CAMKK2 CSNK1A1L NUAK1 CSNK1A1 AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 3.23e-11 | 379 | 104 | 17 | IPR017441 |
| Domain | Pkinase | CDK16 CDK18 CHUK CASK NUAK2 SGK2 CAMKK2 CSNK1A1L NUAK1 CSNK1A1 MASTL AKT1 DCLK2 CDK1 CDK2 CDK3 CDK5 | 3.51e-11 | 381 | 104 | 17 | PF00069 |
| Domain | SMP_LBD | 9.18e-05 | 3 | 104 | 2 | PF17047 | |
| Domain | SMP_LBD | 9.18e-05 | 3 | 104 | 2 | IPR031468 | |
| Domain | Ca/CaM-dep_Ca-dep_prot_Kinase | 5.94e-04 | 69 | 104 | 4 | IPR020636 | |
| Domain | PID | 7.40e-04 | 32 | 104 | 3 | PS01179 | |
| Domain | PDZ | 1.15e-03 | 141 | 104 | 5 | PF00595 | |
| Domain | PTB | 1.43e-03 | 40 | 104 | 3 | SM00462 | |
| Domain | PDZ | 1.43e-03 | 148 | 104 | 5 | SM00228 | |
| Domain | - | 1.52e-03 | 150 | 104 | 5 | 2.30.42.10 | |
| Domain | PTB/PI_dom | 1.53e-03 | 41 | 104 | 3 | IPR006020 | |
| Domain | PDZ | 1.56e-03 | 151 | 104 | 5 | PS50106 | |
| Domain | PDZ | 1.61e-03 | 152 | 104 | 5 | IPR001478 | |
| Domain | - | 1.64e-03 | 42 | 104 | 3 | 3.20.20.70 | |
| Domain | Aldolase_TIM | 1.88e-03 | 44 | 104 | 3 | IPR013785 | |
| Domain | OA_transporter | 1.95e-03 | 12 | 104 | 2 | IPR004156 | |
| Domain | NUDIX_hydrolase_CS | 1.95e-03 | 12 | 104 | 2 | IPR020084 | |
| Domain | OATP | 1.95e-03 | 12 | 104 | 2 | PF03137 | |
| Domain | L27 | 2.30e-03 | 13 | 104 | 2 | SM00569 | |
| Domain | L27 | 2.30e-03 | 13 | 104 | 2 | PS51022 | |
| Domain | L27_dom | 2.30e-03 | 13 | 104 | 2 | IPR004172 | |
| Domain | Acyltransferase | 3.50e-03 | 16 | 104 | 2 | PF01553 | |
| Domain | AGC-kinase_C | 3.75e-03 | 56 | 104 | 3 | IPR000961 | |
| Domain | AGC_KINASE_CTER | 3.75e-03 | 56 | 104 | 3 | PS51285 | |
| Domain | S_TK_X | 3.75e-03 | 56 | 104 | 3 | SM00133 | |
| Domain | PlsC | 3.95e-03 | 17 | 104 | 2 | SM00563 | |
| Domain | Plipid/glycerol_acylTrfase | 3.95e-03 | 17 | 104 | 2 | IPR002123 | |
| Pathway | BIOCARTA_EFP_PATHWAY | 8.44e-07 | 13 | 85 | 4 | MM1537 | |
| Pathway | BIOCARTA_EFP_PATHWAY | 2.12e-06 | 16 | 85 | 4 | M22011 | |
| Pathway | WP_ALZHEIMERS_DISEASE | APC CHUK CSNK1A1L CSNK1A1 AKT1 PLCB3 KIF5C SLC25A31 VDAC1 CDK5 | 3.68e-06 | 261 | 85 | 10 | M42565 |
| Pathway | PID_FOXO_PATHWAY | 1.10e-05 | 49 | 85 | 5 | M136 | |
| Pathway | WP_ALZHEIMERS_DISEASE_AND_MIRNA_EFFECTS | APC CHUK CSNK1A1L CSNK1A1 AKT1 PLCB3 KIF5C SLC25A31 VDAC1 CDK5 | 2.57e-05 | 326 | 85 | 10 | M39379 |
| Pathway | REACTOME_OVARIAN_TUMOR_DOMAIN_PROTEASES | 3.89e-05 | 32 | 85 | 4 | MM15290 | |
| Pathway | WP_WNT_SIGNALING_PATHWAY | 5.22e-05 | 110 | 85 | 6 | MM15977 | |
| Pathway | WP_CHROMOSOMAL_AND_MICROSATELLITE_INSTABILITY_IN_COLORECTAL_CANCER | 7.70e-05 | 73 | 85 | 5 | M39758 | |
| Pathway | PID_FAS_PATHWAY | 7.77e-05 | 38 | 85 | 4 | M94 | |
| Pathway | REACTOME_OVARIAN_TUMOR_DOMAIN_PROTEASES | 8.62e-05 | 39 | 85 | 4 | M27579 | |
| Pathway | REACTOME_BETA_CATENIN_PHOSPHORYLATION_CASCADE | 1.62e-04 | 18 | 85 | 3 | MM14759 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABBERANT_ATXN2_3_TO_MGLUR5_CA2_APOPTOTIC_PATHWAY | 1.62e-04 | 18 | 85 | 3 | M47659 | |
| Pathway | WP_MICROTUBULE_CYTOSKELETON_REGULATION | 1.96e-04 | 48 | 85 | 4 | M39566 | |
| Pathway | KEGG_MEDICUS_REFERENCE_MACHR_CA2_APOPTOTIC_PATHWAY | 2.24e-04 | 20 | 85 | 3 | M47688 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_MACHR_CA2_APOPTOTIC_PATHWAY | 2.60e-04 | 21 | 85 | 3 | M47689 | |
| Pathway | BIOCARTA_AKT_PATHWAY | 3.00e-04 | 22 | 85 | 3 | M15258 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_MGLUR5_CA2_APOPTOTIC_PATHWAY | 3.00e-04 | 22 | 85 | 3 | M47690 | |
| Pathway | KEGG_MEDICUS_REFERENCE_MGLUR5_CA2_APOPTOTIC_PATHWAY | 3.00e-04 | 22 | 85 | 3 | M47675 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_HTT_TO_MGLUR5_CA2_APOPTOTIC_PATHWAY | 3.43e-04 | 23 | 85 | 3 | M47676 | |
| Pathway | REACTOME_CHYLOMICRON_CLEARANCE | 3.55e-04 | 5 | 85 | 2 | M27845 | |
| Pathway | REACTOME_CHYLOMICRON_CLEARANCE | 3.55e-04 | 5 | 85 | 2 | MM15564 | |
| Pathway | REACTOME_REGULATION_OF_TP53_ACTIVITY | 3.67e-04 | 157 | 85 | 6 | MM15226 | |
| Pathway | WP_ANGIOGENESIS | 3.91e-04 | 24 | 85 | 3 | M39556 | |
| Pathway | REACTOME_REGULATION_OF_TP53_ACTIVITY | 4.06e-04 | 160 | 85 | 6 | M27498 | |
| Pathway | REACTOME_TRANSPORT_OF_SMALL_MOLECULES | ESYT1 SLC38A4 IREB2 APOB ADCY2 LDLR SGK2 ESYT2 ABCG1 NALCN ABCA6 NIPA2 VDAC1 | 4.38e-04 | 736 | 85 | 13 | M27287 |
| Pathway | WP_S1P_RECEPTOR_SIGNAL_TRANSDUCTION | 4.42e-04 | 25 | 85 | 3 | M39384 | |
| Pathway | BIOCARTA_AKT_PATHWAY | 4.98e-04 | 26 | 85 | 3 | MM1345 | |
| Pathway | BIOCARTA_RACCYCD_PATHWAY | 4.98e-04 | 26 | 85 | 3 | M14512 | |
| Pathway | BIOCARTA_RACCYCD_PATHWAY | 4.98e-04 | 26 | 85 | 3 | MM1423 | |
| Pathway | WP_WNTBETACATENIN_SIGNALING_IN_LEUKEMIA | 4.98e-04 | 26 | 85 | 3 | M39407 | |
| Pathway | WP_DNA_DAMAGE_RESPONSE_ONLY_ATM_DEPENDENT | 5.27e-04 | 110 | 85 | 5 | M39492 | |
| Pathway | PID_ENDOTHELIN_PATHWAY | 5.59e-04 | 63 | 85 | 4 | M8 | |
| Pathway | PID_REELIN_PATHWAY | 6.22e-04 | 28 | 85 | 3 | M69 | |
| Pathway | PID_LYSOPHOSPHOLIPID_PATHWAY | 6.30e-04 | 65 | 85 | 4 | M15 | |
| Pathway | WP_ONCOSTATIN_M_SIGNALING | 6.30e-04 | 65 | 85 | 4 | M39562 | |
| Pathway | WP_THYROID_STIMULATING_HORMONE_TSH_SIGNALING | 6.68e-04 | 66 | 85 | 4 | M39684 | |
| Pathway | BIOCARTA_REELIN_PATHWAY | 7.40e-04 | 7 | 85 | 2 | M22049 | |
| Pathway | BIOCARTA_REELIN_PATHWAY | 7.40e-04 | 7 | 85 | 2 | MM1566 | |
| Pathway | REACTOME_TRANSPORT_OF_SMALL_MOLECULES | ESYT1 SLC38A4 IREB2 APOB LDLR SGK2 SLCO1B7 ESYT2 ABCG1 NALCN ABCA6 NIPA2 | 7.57e-04 | 681 | 85 | 12 | MM14985 |
| Pathway | PID_RETINOIC_ACID_PATHWAY | 7.64e-04 | 30 | 85 | 3 | M207 | |
| Pathway | PID_EPHRINB_REV_PATHWAY | 7.64e-04 | 30 | 85 | 3 | M257 | |
| Pathway | WP_DNA_DAMAGE_RESPONSE | 7.90e-04 | 69 | 85 | 4 | M39339 | |
| Pathway | WP_UROTENSINIIMEDIATED_SIGNALING | 7.90e-04 | 69 | 85 | 4 | M48052 | |
| Pathway | PID_AR_NONGENOMIC_PATHWAY | 8.42e-04 | 31 | 85 | 3 | M213 | |
| Pathway | REACTOME_DISASSEMBLY_OF_THE_DESTRUCTION_COMPLEX_AND_RECRUITMENT_OF_AXIN_TO_THE_MEMBRANE | 8.42e-04 | 31 | 85 | 3 | MM15154 | |
| Pathway | REACTOME_OPIOID_SIGNALLING | 8.80e-04 | 71 | 85 | 4 | MM14491 | |
| Pathway | WP_AXON_GUIDANCE | 9.27e-04 | 72 | 85 | 4 | M48335 | |
| Pathway | KEGG_MEDICUS_REFERENCE_P4_PR_PI3K_SIGNALING_PATHWAY | 9.83e-04 | 8 | 85 | 2 | M47803 | |
| Pathway | REACTOME_GLYCOSPHINGOLIPID_TRANSPORT | 9.83e-04 | 8 | 85 | 2 | M48263 | |
| Pathway | REACTOME_NETRIN_MEDIATED_REPULSION_SIGNALS | 9.83e-04 | 8 | 85 | 2 | M27328 | |
| Pathway | REACTOME_GLYCOSPHINGOLIPID_TRANSPORT | 9.83e-04 | 8 | 85 | 2 | MM17237 | |
| Pathway | WP_RESISTIN_AS_A_REGULATOR_OF_INFLAMMATION | 1.01e-03 | 33 | 85 | 3 | M39745 | |
| Pathway | KEGG_TIGHT_JUNCTION | 1.20e-03 | 132 | 85 | 5 | M11355 | |
| Pathway | PID_PI3KCI_AKT_PATHWAY | 1.20e-03 | 35 | 85 | 3 | M249 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_SALMONELLA_SOPE_E2_TO_NOD_NFKB_SIGNALING_PATHWAY | 1.26e-03 | 9 | 85 | 2 | M47734 | |
| Pathway | REACTOME_DCC_MEDIATED_ATTRACTIVE_SIGNALING | 1.26e-03 | 9 | 85 | 2 | MM15059 | |
| Pathway | KEGG_MEDICUS_REFERENCE_NOD_NFKB_SIGNALING_PATHWAY | 1.26e-03 | 9 | 85 | 2 | M47652 | |
| Pathway | REACTOME_REGULATION_OF_TP53_DEGRADATION | 1.31e-03 | 36 | 85 | 3 | MM15339 | |
| Pathway | REACTOME_REGULATION_OF_TP53_EXPRESSION_AND_DEGRADATION | 1.42e-03 | 37 | 85 | 3 | M27641 | |
| Pathway | WP_INFLUENCE_OF_LAMINOPATHIES_ON_WNT_SIGNALING | 1.42e-03 | 37 | 85 | 3 | M39817 | |
| Pathway | WP_DNA_IRDAMAGE_AND_CELLULAR_RESPONSE_VIA_ATR | 1.44e-03 | 81 | 85 | 4 | M39490 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_BY_TP53 | 1.45e-03 | 360 | 85 | 8 | M27267 | |
| Pathway | REACTOME_MASTL_FACILITATES_MITOTIC_PROGRESSION | 1.57e-03 | 10 | 85 | 2 | M27176 | |
| Pathway | WP_LIPID_PARTICLES_COMPOSITION | 1.57e-03 | 10 | 85 | 2 | M39697 | |
| Pathway | REACTOME_SYNTHESIS_OF_PYROPHOSPHATES_IN_THE_CYTOSOL | 1.57e-03 | 10 | 85 | 2 | MM14709 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_VGCC_CA2_APOPTOTIC_PATHWAY_N01006 | 1.57e-03 | 10 | 85 | 2 | M47694 | |
| Pathway | REACTOME_SYNTHESIS_OF_PYROPHOSPHATES_IN_THE_CYTOSOL | 1.57e-03 | 10 | 85 | 2 | M27051 | |
| Pathway | REACTOME_REGULATION_OF_COMMISSURAL_AXON_PATHFINDING_BY_SLIT_AND_ROBO | 1.57e-03 | 10 | 85 | 2 | M27348 | |
| Pathway | REACTOME_UREA_CYCLE | 1.57e-03 | 10 | 85 | 2 | M27677 | |
| Pathway | REACTOME_UREA_CYCLE | 1.57e-03 | 10 | 85 | 2 | MM15396 | |
| Pathway | WP_GLIOBLASTOMA_SIGNALING | 1.57e-03 | 83 | 85 | 4 | M39637 | |
| Pathway | REACTOME_G_PROTEIN_MEDIATED_EVENTS | 1.65e-03 | 39 | 85 | 3 | MM14496 | |
| Pathway | PID_ECADHERIN_NASCENT_AJ_PATHWAY | 1.65e-03 | 39 | 85 | 3 | M156 | |
| Pathway | KEGG_PROGESTERONE_MEDIATED_OOCYTE_MATURATION | 1.72e-03 | 85 | 85 | 4 | M3578 | |
| Pathway | WP_BRAINDERIVED_NEUROTROPHIC_FACTOR_BDNF_SIGNALING | 1.77e-03 | 144 | 85 | 5 | M39691 | |
| Pathway | PID_ER_NONGENOMIC_PATHWAY | 1.78e-03 | 40 | 85 | 3 | M41 | |
| Pubmed | A central chaperone-like role for 14-3-3 proteins in human cells. | CDK16 CDK18 ESYT1 APC LMTK2 MPDZ ALPK1 ATAT1 NUAK2 ESYT2 PTPN13 PIK3C2B CSNK1A1 AFDN DCLK2 KIF5C CDK3 VCPIP1 | 9.25e-11 | 861 | 104 | 18 | 36931259 |
| Pubmed | 3.76e-10 | 5 | 104 | 4 | 8601034 | ||
| Pubmed | CDK16 HSPE1 CHUK CASK SGK2 FAT1 NUAK1 CSNK1A1 CDK1 CDK2 CDK3 CDK5 | 3.12e-09 | 401 | 104 | 12 | 25852190 | |
| Pubmed | 3.87e-09 | 78 | 104 | 7 | 17192257 | ||
| Pubmed | 4.25e-09 | 21 | 104 | 5 | 32731332 | ||
| Pubmed | 5.23e-09 | 8 | 104 | 4 | 1639063 | ||
| Pubmed | Association of cyclin-dependent kinase 5 and its activator p35 with apoptotic cell death. | 9.40e-09 | 9 | 104 | 4 | 9438340 | |
| Pubmed | Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics. | ITGB1BP1 APC MPDZ CASK PHKA1 CSNK1A1L CSNK1A1 DYNC1LI1 PLCB3 ENO2 RPL3 MTUS2 | 2.04e-08 | 475 | 104 | 12 | 31040226 |
| Pubmed | Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. | 2.60e-08 | 3 | 104 | 3 | 25242043 | |
| Pubmed | 2.60e-08 | 3 | 104 | 3 | 28655862 | ||
| Pubmed | 4.82e-08 | 33 | 104 | 5 | 20301390 | ||
| Pubmed | Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. | 1.04e-07 | 4 | 104 | 3 | 8242750 | |
| Pubmed | The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic. | 1.04e-07 | 4 | 104 | 3 | 32728212 | |
| Pubmed | 1.04e-07 | 4 | 104 | 3 | 22279592 | ||
| Pubmed | AKT-independent Reelin signaling requires interactions of heterotrimeric Go and Src. | 1.04e-07 | 4 | 104 | 3 | 26441085 | |
| Pubmed | HSPE1 FLNA ESYT1 APC THOC2 TUFM CASK ESYT2 SF3B3 CSNK1A1 DYNC1LI1 CDK1 KIF5C RPL3 | 1.40e-07 | 809 | 104 | 14 | 32129710 | |
| Pubmed | ESYT1 APC MPDZ TIPRL ESYT2 PTPN13 SF3B3 FANCI AFDN CDK1 RPL3 VDAC1 VCPIP1 | 2.07e-07 | 708 | 104 | 13 | 39231216 | |
| Pubmed | CKIα ablation highlights a critical role for p53 in invasiveness control. | 2.59e-07 | 5 | 104 | 3 | 21331045 | |
| Pubmed | A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. | 2.59e-07 | 5 | 104 | 3 | 23890787 | |
| Pubmed | FLNA ESYT1 ANXA6 AGPAT4 DAB2 ZNF622 THOC2 TUFM CHUK LIG3 ESYT2 SF3B3 FANCI DYNC1LI1 CDK1 VDAC1 CDK2 CDK5 | 2.60e-07 | 1440 | 104 | 18 | 30833792 | |
| Pubmed | CDK16 HSPE1 CDK18 FLNA TUFM SF3B3 DYNC1LI1 CDK1 KIF5C ENO2 RPL3 ADGRD1 SLC25A31 CDK2 CDK3 CDK5 | 3.30e-07 | 1153 | 104 | 16 | 29845934 | |
| Pubmed | 3.38e-07 | 397 | 104 | 10 | 21319273 | ||
| Pubmed | Identification and functional characterization of transcriptional activators in human cells. | 3.45e-07 | 398 | 104 | 10 | 35016035 | |
| Pubmed | CDK16 CDK18 FLNA ESYT1 ANXA6 TIPRL NUDT11 FANCI NUDT10 DYNC1LI1 CDK1 CDK2 CDK3 CDK5 | 3.74e-07 | 878 | 104 | 14 | 37223481 | |
| Pubmed | MDMX inhibits casein kinase 1α activity and stimulates Wnt signaling. | 5.16e-07 | 6 | 104 | 3 | 32511789 | |
| Pubmed | 5.16e-07 | 6 | 104 | 3 | 22768111 | ||
| Pubmed | HSPE1 SYNM ESYT1 SRC APC APOB TUFM CASK FAT1 PTPN13 EFNB1 AFDN RPL3 | 5.91e-07 | 777 | 104 | 13 | 35844135 | |
| Pubmed | 9.01e-07 | 7 | 104 | 3 | 9150368 | ||
| Pubmed | 9.01e-07 | 7 | 104 | 3 | 16156789 | ||
| Pubmed | 9.01e-07 | 7 | 104 | 3 | 10896934 | ||
| Pubmed | A Large-scale genetic association study of esophageal adenocarcinoma risk. | 1.16e-06 | 351 | 104 | 9 | 20453000 | |
| Pubmed | The protein interaction landscape of the human CMGC kinase group. | CDK16 CDK18 APC ATAT1 CHUK CASK ESYT2 CDK1 CDK2 JHY CDK3 CDK5 | 1.19e-06 | 695 | 104 | 12 | 23602568 |
| Pubmed | A Human Tyrosine Phosphatase Interactome Mapped by Proteomic Profiling. | FLNA ESYT1 MPDZ TIPRL CASK ESYT2 CSNK1A1L CSNK1A1 FANCI AFDN CDK1 RPL3 CDK2 VCPIP1 | 1.28e-06 | 974 | 104 | 14 | 28675297 |
| Pubmed | 1.32e-06 | 263 | 104 | 8 | 34702444 | ||
| Pubmed | Large-scale mapping of human protein-protein interactions by mass spectrometry. | HSPE1 TIPRL TUFM KMT2C LIG3 SF3B3 NUAK1 TIMP2 FANCI RAD54B AFDN KIF5C RPL3 ELL VDAC1 CDK2 | 1.36e-06 | 1284 | 104 | 16 | 17353931 |
| Pubmed | HSPE1 FLNA ESYT1 DAB2 THOC2 TUFM ESYT2 CSNK1A1 AFDN CDK1 RPL3 VDAC1 | 1.43e-06 | 707 | 104 | 12 | 19738201 | |
| Pubmed | 1.44e-06 | 8 | 104 | 3 | 12526740 | ||
| Pubmed | 1.44e-06 | 8 | 104 | 3 | 22654103 | ||
| Pubmed | The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. | 1.44e-06 | 8 | 104 | 3 | 10884347 | |
| Pubmed | A high-throughput approach for measuring temporal changes in the interactome. | HSPE1 FLNA TES ANXA6 ZNF622 IREB2 GMPR2 TUFM CHUK GLA FANCI DYNC1LI1 PLCB3 CDK1 ENO2 RPL3 VCPIP1 | 1.47e-06 | 1455 | 104 | 17 | 22863883 |
| Pubmed | Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. | 1.48e-06 | 117 | 104 | 6 | 19124506 | |
| Pubmed | Tumor suppressor BAP1 nuclear import is governed by transportin-1. | HSPE1 FLNA MPDZ TUFM PHKA1 LIG3 SF3B3 FANCI DYNC1LI1 AFDN HAGH CDK1 ENO2 RPL3 VDAC1 | 1.70e-06 | 1149 | 104 | 15 | 35446349 |
| Pubmed | Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. | 1.87e-06 | 372 | 104 | 9 | 22939624 | |
| Pubmed | PTEN identified as important risk factor of chronic obstructive pulmonary disease. | 1.95e-06 | 374 | 104 | 9 | 19625176 | |
| Pubmed | NMNAT1 SRC APC LDLR SGK2 AKT1 PLCB3 CDK1 CARS2 RPL3 CDK2 CDK3 | 1.98e-06 | 730 | 104 | 12 | 34857952 | |
| Pubmed | Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. | NRIP1 ANXA6 SRC DAB1 ATAT1 CASK SGK2 KMT2C ESYT2 ABCG1 PTPN13 TIMP2 CSNK1A1 DCLK2 KIF5C ADGRD1 PDZD2 | 2.01e-06 | 1489 | 104 | 17 | 28611215 |
| Pubmed | Cooperative polarization of MCAM/CD146 and ERM family proteins in melanoma. | 2.09e-06 | 377 | 104 | 9 | 38117590 | |
| Pubmed | 2.15e-06 | 9 | 104 | 3 | 9601641 | ||
| Pubmed | 2.15e-06 | 9 | 104 | 3 | 25483085 | ||
| Pubmed | Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China. | 2.32e-06 | 382 | 104 | 9 | 19170196 | |
| Pubmed | 2.74e-06 | 203 | 104 | 7 | 19953087 | ||
| Pubmed | 3.07e-06 | 10 | 104 | 3 | 22027834 | ||
| Pubmed | 3.27e-06 | 34 | 104 | 4 | 23342106 | ||
| Pubmed | Multiplexed kinase interactome profiling quantifies cellular network activity and plasticity. | SRC CHUK NUAK2 PHKA1 CAMKK2 CSNK1A1L NUAK1 CSNK1A1 AKT1 CDK1 CDK2 CDK3 CDK5 | 3.37e-06 | 910 | 104 | 13 | 36736316 |
| Pubmed | FLNA ESYT1 THOC2 TUFM ESYT2 SF3B3 FANCI DYNC1LI1 CDK1 RPL3 VDAC1 | 3.47e-06 | 638 | 104 | 11 | 33239621 | |
| Pubmed | Probing nuclear pore complex architecture with proximity-dependent biotinylation. | 3.61e-06 | 77 | 104 | 5 | 24927568 | |
| Pubmed | Multiple newly identified loci associated with prostate cancer susceptibility. | 4.21e-06 | 11 | 104 | 3 | 18264097 | |
| Pubmed | 4.21e-06 | 11 | 104 | 3 | 12190313 | ||
| Pubmed | N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective. | FLNA TES ESYT1 ZNF622 TIPRL THOC2 LIG3 PTPN13 MASTL RPL3 VDAC1 CDK2 VCPIP1 | 4.47e-06 | 934 | 104 | 13 | 33916271 |
| Pubmed | Assembly of the U5 snRNP component PRPF8 is controlled by the HSP90/R2TP chaperones. | HSPE1 FLNA ZNF622 CPS1 LDLR TUFM SF3B3 CSNK1A1 PLCB3 HAGH CDK1 CARS2 RPL3 VDAC1 CDK2 VCPIP1 | 4.70e-06 | 1415 | 104 | 16 | 28515276 |
| Pubmed | Genetic susceptibility to distinct bladder cancer subphenotypes. | 5.11e-06 | 421 | 104 | 9 | 19692168 | |
| Pubmed | Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation. | HSPE1 FLNA ESYT1 ANXA6 APOB THOC2 TUFM LIG3 SF3B3 FANCI DYNC1LI1 AFDN CDK1 RPL3 VDAC1 CDK2 | 5.14e-06 | 1425 | 104 | 16 | 30948266 |
| Pubmed | HSPE1 FLNA ESYT1 ANXA6 TUFM SF3B3 CDK1 KIF5C ENO2 RPL3 VDAC1 CDK2 | 5.25e-06 | 803 | 104 | 12 | 36517590 | |
| Pubmed | FLNA APC TUFM CASK NUAK2 CSNK1A1L SF3B3 CSNK1A1 AFDN DCLK2 KIF5C ENO2 RPL3 MTUS2 VDAC1 CDK5 | 5.42e-06 | 1431 | 104 | 16 | 37142655 | |
| Pubmed | CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. | 5.60e-06 | 12 | 104 | 3 | 24218572 | |
| Pubmed | 5.60e-06 | 12 | 104 | 3 | 19884882 | ||
| Pubmed | 5.90e-06 | 322 | 104 | 8 | 26514267 | ||
| Pubmed | 6.13e-06 | 549 | 104 | 10 | 38280479 | ||
| Pubmed | Interlaboratory reproducibility of large-scale human protein-complex analysis by standardized AP-MS. | 6.28e-06 | 432 | 104 | 9 | 23455922 | |
| Pubmed | 6.60e-06 | 87 | 104 | 5 | 33798452 | ||
| Pubmed | Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. | 6.60e-06 | 327 | 104 | 8 | 15592455 | |
| Pubmed | 6.90e-06 | 329 | 104 | 8 | 17474147 | ||
| Pubmed | 7.27e-06 | 13 | 104 | 3 | 28031458 | ||
| Pubmed | HSPE1 FLNA NPR3 ESYT1 APC APOB TIPRL LDLR FAT1 GLA HAGH CDK1 CARS2 RPL3 CDK2 | 7.36e-06 | 1297 | 104 | 15 | 33545068 | |
| Pubmed | Yeast as a model system to screen purine derivatives against human CDK1 and CDK2 kinases. | 8.86e-06 | 2 | 104 | 2 | 25541464 | |
| Pubmed | [A genetic and clinical study in a family with familial hypercholesterolemia]. | 8.86e-06 | 2 | 104 | 2 | 21418831 | |
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 36709358 | ||
| Pubmed | DCC constrains tumour progression via its dependence receptor activity. | 8.86e-06 | 2 | 104 | 2 | 22158121 | |
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 23354688 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 18981479 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 18787066 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 36950286 | ||
| Pubmed | Tissue-specific distribution of mouse casein kinase I alpha mRNA. | 8.86e-06 | 2 | 104 | 2 | 9522121 | |
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 18354084 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 24349031 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 20019594 | ||
| Pubmed | Echium oil reduces atherosclerosis in apoB100-only LDLrKO mice. | 8.86e-06 | 2 | 104 | 2 | 22100249 | |
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 21357823 | ||
| Pubmed | Casein Kinase 1α Regulates Testosterone Synthesis and Testis Development in Adult Mice. | 8.86e-06 | 2 | 104 | 2 | 36929849 | |
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 22268108 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 12689335 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 37626870 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 15637307 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 22837469 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 26178198 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 25482200 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 19834103 | ||
| Pubmed | Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a western diet. | 8.86e-06 | 2 | 104 | 2 | 17070501 | |
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 25830298 | ||
| Pubmed | 8.86e-06 | 2 | 104 | 2 | 24362465 | ||
| Interaction | HSP90AB1 interactions | HSPE1 CDK18 FLNA TES RBM45 SRC CPS1 THOC2 TUFM CHUK SGK2 KMT2C NOD1 TIMP2 CSNK1A1 ASXL3 AKT1 DCLK2 RPL3 CDK2 CDK3 CDK5 | 2.49e-09 | 960 | 103 | 22 | int:HSP90AB1 |
| Interaction | HSP90AA1 interactions | HSPE1 CDK18 FLNA SRC APOB ALPK1 CPS1 THOC2 TUFM CHUK NUAK2 SGK2 CAMKK2 NOD1 SF3B3 CSNK1A1 ASXL3 AKT1 DCLK2 CDK1 RPL3 CDK2 CDK3 CDK5 | 1.61e-08 | 1263 | 103 | 24 | int:HSP90AA1 |
| Interaction | CCNI interactions | 4.61e-08 | 20 | 103 | 5 | int:CCNI | |
| Interaction | PHLPP1 interactions | FLNA SYNM ESYT1 DAB2 APC LDLR EFNB1 CSNK1A1 FANCI AKT1 RPL3 VCPIP1 | 1.35e-07 | 333 | 103 | 12 | int:PHLPP1 |
| Interaction | YWHAH interactions | CDK16 CDK18 NRIP1 ESYT1 SRC APC LMTK2 MPDZ ATAT1 NUAK2 ESYT2 PTPN13 NUAK1 PIK3C2B CSNK1A1 AFDN DCLK2 KIF5C CDK2 CDK3 VCPIP1 | 1.44e-07 | 1102 | 103 | 21 | int:YWHAH |
| Interaction | SPDYE4 interactions | 6.80e-07 | 61 | 103 | 6 | int:SPDYE4 | |
| Interaction | CDKN1B interactions | 7.50e-07 | 144 | 103 | 8 | int:CDKN1B | |
| Interaction | CDK5R1 interactions | 9.96e-07 | 65 | 103 | 6 | int:CDK5R1 | |
| Interaction | FKBP5 interactions | CDK18 CHUK SGK2 CAMKK2 CSNK1A1 FANCI RAD54B AKT1 DCLK2 CDK1 CDK3 CDK5 | 1.37e-06 | 414 | 103 | 12 | int:FKBP5 |
| Interaction | SPDYE1 interactions | 2.56e-06 | 6 | 103 | 3 | int:SPDYE1 | |
| Interaction | CDK5 interactions | 4.21e-06 | 242 | 103 | 9 | int:CDK5 | |
| Interaction | YWHAG interactions | CDK16 CDK18 FLNA ESYT1 SRC APC LMTK2 MPDZ ATAT1 ESYT2 PTPN13 SF3B3 NUAK1 PIK3C2B CSNK1A1 AFDN AKT1 DCLK2 KIF5C CDK2 | 4.39e-06 | 1248 | 103 | 20 | int:YWHAG |
| Interaction | YWHAE interactions | CDK16 CDK18 FLNA ESYT1 SRC APC ATAT1 CASK NUAK2 PTPN13 NUAK1 PIK3C2B CSNK1A1 DYNC1LI1 AFDN AKT1 DCLK2 VDAC1 CDK2 CDK3 | 4.83e-06 | 1256 | 103 | 20 | int:YWHAE |
| Interaction | EZR interactions | HSPE1 APC ZNF622 DCC FASLG CASK EFNB1 DYNC1LI1 PLCB3 KIF5C ENO2 VDAC1 CDK5 | 4.87e-06 | 553 | 103 | 13 | int:EZR |
| Interaction | CKS2 interactions | 5.04e-06 | 49 | 103 | 5 | int:CKS2 | |
| Interaction | ZDHHC11 interactions | 5.29e-06 | 23 | 103 | 4 | int:ZDHHC11 | |
| Interaction | PIP5K1C interactions | 5.58e-06 | 50 | 103 | 5 | int:PIP5K1C | |
| Interaction | CCND3 interactions | 7.22e-06 | 91 | 103 | 6 | int:CCND3 | |
| Interaction | KCNA3 interactions | NRIP1 ESYT1 APC MPDZ TIPRL THOC2 KMT2C ESYT2 PTPN13 SF3B3 FANCI AFDN CDK1 RPL3 VDAC1 VCPIP1 | 8.54e-06 | 871 | 103 | 16 | int:KCNA3 |
| Interaction | BAP1 interactions | HSPE1 FLNA MPDZ CPS1 TUFM PHKA1 KMT2C LIG3 FAT1 SF3B3 FANCI ASXL3 DYNC1LI1 AFDN AKT1 HAGH CDK1 ENO2 RPL3 VDAC1 | 9.44e-06 | 1314 | 103 | 20 | int:BAP1 |
| Interaction | PFN1 interactions | HSPE1 APC PHKA1 ESYT2 TIMP2 DYNC1LI1 AFDN HAGH ELL VDAC1 CDK2 VCPIP1 | 1.13e-05 | 509 | 103 | 12 | int:PFN1 |
| Interaction | CDC25A interactions | 1.25e-05 | 151 | 103 | 7 | int:CDC25A | |
| Interaction | STIP1 interactions | HSPE1 FLNA ESYT1 THOC2 LDLR TUFM LIG3 ESYT2 SF3B3 FANCI DYNC1LI1 CDK1 ENO2 RPL3 VDAC1 CDK3 CDK5 | 1.29e-05 | 1006 | 103 | 17 | int:STIP1 |
| Interaction | HEXIM1 interactions | CDK16 HSPE1 CDK18 FLNA LDLR SF3B3 DYNC1LI1 CDK1 KIF5C ENO2 RPL3 ADGRD1 SLC25A31 CDK2 CDK3 CDK5 | 1.53e-05 | 913 | 103 | 16 | int:HEXIM1 |
| Interaction | LYN interactions | CDK16 ESYT1 SRC APC LMTK2 FASLG CASK ESYT2 PTPN13 EFNB1 TGDS AFDN CDK1 CDK2 | 1.77e-05 | 720 | 103 | 14 | int:LYN |
| Interaction | CCNO interactions | 1.82e-05 | 31 | 103 | 4 | int:CCNO | |
| Interaction | SKP2 interactions | 2.11e-05 | 296 | 103 | 9 | int:SKP2 | |
| Interaction | RAC1 interactions | HSPE1 FLNA ESYT1 ITGB1BP1 SRC DAB2 CASK ESYT2 FAT1 PTPN13 EFNB1 CSNK1A1 AKT1 PLCB3 RPL3 CDK2 CDK5 | 2.61e-05 | 1063 | 103 | 17 | int:RAC1 |
| Interaction | ITGB3 interactions | 2.70e-05 | 170 | 103 | 7 | int:ITGB3 | |
| Interaction | HK1 interactions | 2.70e-05 | 234 | 103 | 8 | int:HK1 | |
| Interaction | CAMKK2 interactions | 2.74e-05 | 69 | 103 | 5 | int:CAMKK2 | |
| Interaction | SPDYA interactions | 2.76e-05 | 12 | 103 | 3 | int:SPDYA | |
| Interaction | RGCC interactions | 2.76e-05 | 12 | 103 | 3 | int:RGCC | |
| Interaction | VCAM1 interactions | HSPE1 FLNA ESYT1 THOC2 TUFM EFNB1 CSNK1A1 AFDN CDK1 RPL3 VDAC1 | 3.15e-05 | 475 | 103 | 11 | int:VCAM1 |
| Interaction | ARL14 interactions | 3.35e-05 | 119 | 103 | 6 | int:ARL14 | |
| Interaction | FLT3 interactions | 3.71e-05 | 318 | 103 | 9 | int:FLT3 | |
| Interaction | RHOF interactions | ESYT1 DAB2 MPDZ CASK LIG3 ESYT2 FAT1 PTPN13 EFNB1 FANCI DYNC1LI1 PLCB3 CDK5 | 3.87e-05 | 673 | 103 | 13 | int:RHOF |
| Interaction | FOXO3 interactions | 4.22e-05 | 124 | 103 | 6 | int:FOXO3 | |
| Interaction | CDK2 interactions | CDK16 HSPE1 FLNA TES ESYT1 TUFM SF3B3 CDK1 ENO2 RPL3 VDAC1 CDK2 CDK3 CDK5 | 4.44e-05 | 783 | 103 | 14 | int:CDK2 |
| Interaction | UCHL1 interactions | 4.70e-05 | 253 | 103 | 8 | int:UCHL1 | |
| Interaction | CDK1 interactions | CDK18 FLNA TES SRC DAB2 ASXL3 AKT1 CDK1 VDAC1 CDK2 CDK3 CDK5 | 4.79e-05 | 590 | 103 | 12 | int:CDK1 |
| Interaction | CTNNB1 interactions | HSPE1 TES SRC APC MPDZ CHUK LIG3 ABCG1 PTPN13 CSNK1A1 AFDN AKT1 CDK1 RPL3 CDK2 VCPIP1 | 5.14e-05 | 1009 | 103 | 16 | int:CTNNB1 |
| Interaction | PAFAH1B1 interactions | 5.39e-05 | 258 | 103 | 8 | int:PAFAH1B1 | |
| Interaction | HMGB2 interactions | 5.39e-05 | 258 | 103 | 8 | int:HMGB2 | |
| Interaction | CDKN1C interactions | 5.63e-05 | 41 | 103 | 4 | int:CDKN1C | |
| Interaction | CDK18 interactions | 5.74e-05 | 131 | 103 | 6 | int:CDK18 | |
| Interaction | CDC25B interactions | 6.51e-05 | 134 | 103 | 6 | int:CDC25B | |
| Interaction | HDAC5 interactions | 7.37e-05 | 432 | 103 | 10 | int:HDAC5 | |
| Interaction | CAV1 interactions | FLNA SLC31A2 ESYT1 ANXA6 SRC APC LMTK2 CASK ESYT2 PTPN13 EFNB1 AFDN VDAC1 | 8.14e-05 | 724 | 103 | 13 | int:CAV1 |
| Interaction | RPS6KB1 interactions | 9.34e-05 | 143 | 103 | 6 | int:RPS6KB1 | |
| Interaction | SERBP1 interactions | CDK16 CDK18 FLNA ESYT1 ANXA6 TIPRL LDLR NUDT11 SF3B3 TIMP2 CSNK1A1 FANCI NUDT10 DYNC1LI1 CDK1 RPL3 CDK2 CDK3 CDK5 | 1.06e-04 | 1432 | 103 | 19 | int:SERBP1 |
| Interaction | DPP4 interactions | 1.09e-04 | 453 | 103 | 10 | int:DPP4 | |
| Interaction | ASXL1 interactions | 1.11e-04 | 286 | 103 | 8 | int:ASXL1 | |
| Interaction | ARRB2 interactions | 1.11e-04 | 454 | 103 | 10 | int:ARRB2 | |
| Interaction | FGR interactions | 1.15e-04 | 93 | 103 | 5 | int:FGR | |
| Interaction | PGRMC1 interactions | 1.31e-04 | 375 | 103 | 9 | int:PGRMC1 | |
| Interaction | CDKN1A interactions | 1.31e-04 | 375 | 103 | 9 | int:CDKN1A | |
| Interaction | MCAM interactions | 1.42e-04 | 468 | 103 | 10 | int:MCAM | |
| Interaction | KIF26B interactions | 1.44e-04 | 52 | 103 | 4 | int:KIF26B | |
| Interaction | PPP1CB interactions | 1.45e-04 | 469 | 103 | 10 | int:PPP1CB | |
| Interaction | SRC interactions | 1.47e-04 | 664 | 103 | 12 | int:SRC | |
| Interaction | CDC25C interactions | 1.51e-04 | 156 | 103 | 6 | int:CDC25C | |
| Interaction | YWHAQ interactions | CDK16 CDK18 FLNA NRIP1 APC CPS1 ATAT1 PTPN13 EFNB1 PIK3C2B CSNK1A1 AFDN DCLK2 KIF5C CDK2 CDK3 | 1.70e-04 | 1118 | 103 | 16 | int:YWHAQ |
| Interaction | MAPT interactions | FLNA ANXA6 SRC TUFM CASK CSNK1A1 AFDN AKT1 DCLK2 CDK1 KIF5C CARS2 ENO2 VDAC1 CDK2 CDK5 | 1.72e-04 | 1119 | 103 | 16 | int:MAPT |
| Interaction | CDKN3 interactions | 1.80e-04 | 55 | 103 | 4 | int:CDKN3 | |
| Interaction | DAB2IP interactions | 1.86e-04 | 103 | 103 | 5 | int:DAB2IP | |
| Interaction | ARHGAP24 interactions | 1.93e-04 | 486 | 103 | 10 | int:ARHGAP24 | |
| Interaction | YWHAB interactions | CDK16 CDK18 ESYT1 SRC APC ATAT1 ESYT2 PTPN13 NUAK1 PIK3C2B DYNC1LI1 AFDN DCLK2 KIF5C CDK3 | 1.94e-04 | 1014 | 103 | 15 | int:YWHAB |
| Interaction | GJA1 interactions | 1.94e-04 | 583 | 103 | 11 | int:GJA1 | |
| Interaction | C11orf52 interactions | 1.96e-04 | 311 | 103 | 8 | int:C11orf52 | |
| Interaction | MDM4 interactions | 2.04e-04 | 105 | 103 | 5 | int:MDM4 | |
| Interaction | ASXL3 interactions | 2.04e-04 | 165 | 103 | 6 | int:ASXL3 | |
| Interaction | RASA1 interactions | 2.18e-04 | 167 | 103 | 6 | int:RASA1 | |
| Interaction | IQGAP1 interactions | 2.19e-04 | 591 | 103 | 11 | int:IQGAP1 | |
| Interaction | RPE interactions | 2.21e-04 | 58 | 103 | 4 | int:RPE | |
| Interaction | DAB1 interactions | 2.22e-04 | 107 | 103 | 5 | int:DAB1 | |
| Interaction | AFAP1 interactions | 2.68e-04 | 61 | 103 | 4 | int:AFAP1 | |
| Interaction | USP32 interactions | 2.99e-04 | 114 | 103 | 5 | int:USP32 | |
| Interaction | MAPK15 interactions | 3.04e-04 | 63 | 103 | 4 | int:MAPK15 | |
| Interaction | FOXRED1 interactions | 3.23e-04 | 64 | 103 | 4 | int:FOXRED1 | |
| Interaction | DCK interactions | 3.43e-04 | 65 | 103 | 4 | int:DCK | |
| Interaction | CBY1 interactions | 3.46e-04 | 182 | 103 | 6 | int:CBY1 | |
| Interaction | RHOB interactions | CDK16 ESYT1 SRC DAB2 CASK ESYT2 FAT1 PTPN13 EFNB1 CSNK1A1 AFDN RPL3 CDK5 | 3.50e-04 | 840 | 103 | 13 | int:RHOB |
| Interaction | YWHAZ interactions | CDK16 CDK18 ESYT1 APC ATAT1 TUFM NUAK2 PTPN13 PIK3C2B CSNK1A1 ASXL3 DYNC1LI1 AFDN AKT1 KIF5C VDAC1 CDK2 | 3.59e-04 | 1319 | 103 | 17 | int:YWHAZ |
| Interaction | LIN7C interactions | 3.64e-04 | 119 | 103 | 5 | int:LIN7C | |
| Interaction | FGFR1 interactions | CDK16 ESYT1 SRC CASK PTPN13 FANCI AKT1 CDK1 KIF5C VDAC1 CDK2 | 3.87e-04 | 632 | 103 | 11 | int:FGFR1 |
| Interaction | BAAT interactions | 3.87e-04 | 28 | 103 | 3 | int:BAAT | |
| Interaction | CCNE2 interactions | 3.87e-04 | 28 | 103 | 3 | int:CCNE2 | |
| Interaction | CCNE1 interactions | 3.93e-04 | 121 | 103 | 5 | int:CCNE1 | |
| Interaction | RHBDD1 interactions | 4.02e-04 | 346 | 103 | 8 | int:RHBDD1 | |
| Interaction | BIRC3 interactions | HSPE1 FLNA ESYT1 ANXA6 APOB THOC2 TUFM CHUK LIG3 SF3B3 FANCI DYNC1LI1 AFDN CDK1 RPL3 VDAC1 CDK2 | 4.10e-04 | 1334 | 103 | 17 | int:BIRC3 |
| Interaction | HDAC4 interactions | CDK16 ITGB1BP1 APC MPDZ CASK PHKA1 CSNK1A1 DYNC1LI1 PLCB3 RPL3 MTUS2 CDK5 | 4.14e-04 | 744 | 103 | 12 | int:HDAC4 |
| Interaction | SORBS1 interactions | 4.24e-04 | 123 | 103 | 5 | int:SORBS1 | |
| Interaction | CALD1 interactions | 4.25e-04 | 265 | 103 | 7 | int:CALD1 | |
| Interaction | TOP3B interactions | FLNA ESYT1 LMTK2 IREB2 APOB THOC2 LDLR TUFM KMT2C LIG3 FAT1 NUAK1 PIK3C2B CSNK1A1 FANCI AKT1 ELL VDAC1 | 4.39e-04 | 1470 | 103 | 18 | int:TOP3B |
| Interaction | CDC37 interactions | 4.59e-04 | 645 | 103 | 11 | int:CDC37 | |
| Interaction | NEDD4 interactions | 4.71e-04 | 544 | 103 | 10 | int:NEDD4 | |
| Interaction | SH3PXD2A interactions | 5.09e-04 | 128 | 103 | 5 | int:SH3PXD2A | |
| Interaction | TMPO interactions | FLNA ESYT1 SRC ZNF622 APOB LIG3 ESYT2 SF3B3 CSNK1A1 CDK1 RPL3 MTUS2 | 5.12e-04 | 762 | 103 | 12 | int:TMPO |
| Interaction | CCDC8 interactions | 5.28e-04 | 656 | 103 | 11 | int:CCDC8 | |
| GeneFamily | Cyclin dependent kinases | 4.90e-10 | 26 | 68 | 6 | 496 | |
| GeneFamily | Extended synaptotagmins | 4.17e-05 | 3 | 68 | 2 | 827 | |
| GeneFamily | PDZ domain containing | 2.68e-04 | 152 | 68 | 5 | 1220 | |
| GeneFamily | Solute carriers | 6.94e-04 | 395 | 68 | 7 | 752 | |
| GeneFamily | 1-acylglycerol-3-phosphate O-acyltransferases | 7.50e-04 | 11 | 68 | 2 | 46 | |
| GeneFamily | Ring finger proteins|Fanconi anemia complementation groups|Protein phosphatase 1 regulatory subunits|BRCA1 A complex|BRCA1 B complex|BRCA1 C complex | 2.53e-03 | 20 | 68 | 2 | 548 | |
| GeneFamily | Nudix hydrolase family | 3.65e-03 | 24 | 68 | 2 | 667 | |
| Coexpression | MILI_PSEUDOPODIA_CHEMOTAXIS_DN | ESYT1 SLC38A4 GMPR2 ATAT1 LDLR CHUK PIK3IP1 SF3B3 GLA TIMP2 RPL3 | 2.09e-06 | 457 | 104 | 11 | M1613 |
| Coexpression | WANG_SMARCE1_TARGETS_UP | 2.69e-06 | 294 | 104 | 9 | M1804 | |
| Coexpression | MILI_PSEUDOPODIA_CHEMOTAXIS_DN | ESYT1 SLC38A4 GMPR2 ATAT1 LDLR CHUK PIK3IP1 SF3B3 GLA TIMP2 RPL3 | 2.73e-06 | 470 | 104 | 11 | MM1053 |
| Coexpression | HALLMARK_PI3K_AKT_MTOR_SIGNALING | 3.95e-06 | 105 | 104 | 6 | M5923 | |
| Coexpression | FUJII_YBX1_TARGETS_DN | 1.27e-05 | 194 | 104 | 7 | M14340 | |
| Coexpression | CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN | NRIP1 NPR3 LDLR TUFM NUDT11 FANCI RAD54B DYNC1LI1 CDK1 ENO2 RPL3 VDAC1 | 1.41e-05 | 669 | 104 | 12 | M18635 |
| Coexpression | HE_LIM_SUN_FETAL_LUNG_C1_EARLY_STALK_CELL | BRIP1 AGPAT4 LDLR NUDT11 EFNB1 NUAK1 FANCI RAD54B MASTL PLCB3 CDK1 | 1.60e-05 | 567 | 104 | 11 | M45692 |
| Coexpression | GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN | SLC31A2 AGPAT4 DAB2 DCC ATAT1 THOC2 SGK2 PIK3IP1 NOD1 TIMP2 TGDS RAD54B MASTL CDK5 DNMT3B | 2.96e-05 | 1102 | 104 | 15 | M2369 |
| Coexpression | BLALOCK_ALZHEIMERS_DISEASE_DN | CDK16 HSPE1 NRIP1 ITGB1BP1 APC GMPR2 ADCY2 TUFM CAMKK2 NUDT11 DYNC1LI1 KIF5C ENO2 VDAC1 CDK5 SLC35B1 | 3.23e-05 | 1248 | 104 | 16 | M17728 |
| Coexpression | GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN | SLC31A2 AGPAT4 DAB2 DCC ATAT1 THOC2 SGK2 PIK3IP1 NOD1 TIMP2 TGDS RAD54B MASTL CDK5 DNMT3B | 3.71e-05 | 1124 | 104 | 15 | MM1070 |
| Coexpression | DUTERTRE_ESTRADIOL_RESPONSE_24HR_UP | 4.50e-05 | 323 | 104 | 8 | M2156 | |
| Coexpression | MULLIGHAN_NPM1_SIGNATURE_3_DN | 4.52e-05 | 161 | 104 | 6 | M15047 | |
| Coexpression | GSE37301_HEMATOPOIETIC_STEM_CELL_VS_GRAN_MONO_PROGENITOR_DN | 7.41e-05 | 176 | 104 | 6 | M8884 | |
| Coexpression | MILI_PSEUDOPODIA_HAPTOTAXIS_DN | FLNA ESYT1 SLC38A4 LMTK2 LDLR CHUK ESYT2 SF3B3 EFNB1 GLA TIMP2 | 8.40e-05 | 681 | 104 | 11 | M5314 |
| Coexpression | MILI_PSEUDOPODIA_HAPTOTAXIS_DN | FLNA ESYT1 SLC38A4 LMTK2 LDLR CHUK ESYT2 SF3B3 EFNB1 GLA TIMP2 | 1.11e-04 | 703 | 104 | 11 | MM1055 |
| Coexpression | FOURNIER_ACINAR_DEVELOPMENT_LATE_2 | 1.32e-04 | 281 | 104 | 7 | M4077 | |
| Coexpression | LINDGREN_BLADDER_CANCER_CLUSTER_1_DN | 1.34e-04 | 378 | 104 | 8 | M17788 | |
| Coexpression | GSE18791_UNSTIM_VS_NEWCATSLE_VIRUS_DC_10H_DN | 1.38e-04 | 197 | 104 | 6 | M4294 | |
| Coexpression | GSE40685_NAIVE_CD4_TCELL_VS_FOXP3_KO_TREG_PRECURSOR_UP | 1.49e-04 | 200 | 104 | 6 | M9304 | |
| Coexpression | GSE1432_1H_VS_24H_IFNG_MICROGLIA_UP | 1.49e-04 | 200 | 104 | 6 | M3413 | |
| Coexpression | GSE17186_CD21LOW_VS_CD21HIGH_TRANSITIONAL_BCELL_DN | 1.49e-04 | 200 | 104 | 6 | M7174 | |
| Coexpression | GSE32423_MEMORY_VS_NAIVE_CD8_TCELL_UP | 1.49e-04 | 200 | 104 | 6 | M5072 | |
| Coexpression | GSE2585_CTEC_VS_THYMIC_DC_DN | 1.49e-04 | 200 | 104 | 6 | M6272 | |
| Coexpression | DACOSTA_UV_RESPONSE_VIA_ERCC3_DN | NRIP1 DPYD APC TIPRL THOC2 LDLR CASK FAT1 PTPN13 NUAK1 CSNK1A1 KIF5C | 1.50e-04 | 856 | 104 | 12 | M4500 |
| Coexpression | GABRIELY_MIR21_TARGETS | 1.57e-04 | 289 | 104 | 7 | M2196 | |
| Coexpression | KRIEG_HYPOXIA_NOT_VIA_KDM3A | CDK18 FLNA TES SLC31A2 CASK NUAK1 FANCI MASTL CARS2 ENO2 VDAC1 | 1.86e-04 | 746 | 104 | 11 | M2469 |
| Coexpression | KOKKINAKIS_METHIONINE_DEPRIVATION_96HR_DN | 1.96e-04 | 72 | 104 | 4 | M170 | |
| ToppCell | droplet-Lung-LUNG-1m-Myeloid-Proliferating_Alveolar_Macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.71e-07 | 194 | 104 | 7 | effd38e51062b225ecabc7e1c50154e65495d559 | |
| ToppCell | droplet-Lung-1m-Hematologic-myeloid-alveolar_macrophage-proliferating_alveolar_macrophage|1m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 3.84e-07 | 195 | 104 | 7 | c1435e61e4f0cf457f26ae436936048932ceb0db | |
| ToppCell | Control-Endothelial-VE_Arterial|Endothelial / Disease state, Lineage and Cell class | 5.99e-06 | 192 | 104 | 6 | 7e89b9125e8b85f6be85eeccef5c8644647ab0e1 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_cycling-mes_proliferating1_(3)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 6.54e-06 | 195 | 104 | 6 | b65463a804fed2d9a3be9e528ca8b9c98469bc86 | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_cycling-mes_proliferating1_(3)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 6.54e-06 | 195 | 104 | 6 | 56d8734d020b3da08a5aa9e67999706a9e023a99 | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_cycling-mes_proliferating1_(3)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 6.74e-06 | 196 | 104 | 6 | df366d76ea55f49e349d622effa57c1535df8400 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_myocytic-Myofibroblastic|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 7.56e-06 | 200 | 104 | 6 | 08bf8c00eee6468215edb3611296bfc8784c4d56 | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-10w-Neuronal-Intermediate|10w / Sample Type, Dataset, Time_group, and Cell type. | 7.56e-06 | 200 | 104 | 6 | e5a8647c47a49c8c90c78d681193946de103d8ff | |
| ToppCell | 3'-Adult-SmallIntestine-Epithelial-mature_enterocytic-Paneth|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.92e-05 | 162 | 104 | 5 | 768a566e76923323c1f197f60bab472a8784490b | |
| ToppCell | 3'_v3-lymph-node_spleen-Hematopoietic_progenitors-Progenitor|lymph-node_spleen / Manually curated celltypes from each tissue | 4.54e-05 | 167 | 104 | 5 | cb396f3edb9e8fdc316091e8e193dbba50e0be0c | |
| ToppCell | PND14-Immune-Immune_Myeloid-Monocytic-Macrophage-IM-IM_prolif|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 5.08e-05 | 171 | 104 | 5 | bf475a69db04d4a886e442704955c6a96ff0de46 | |
| ToppCell | droplet-Liver-Hepatocytes-21m-Myeloid-Kupffer_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.22e-05 | 172 | 104 | 5 | 574ebdf36e45222bcd907cd2c2ee7ff50ed4573a | |
| ToppCell | 3'_v3-GI_small-bowel-Lymphocytic_NK-NK_CD16|GI_small-bowel / Manually curated celltypes from each tissue | 5.22e-05 | 172 | 104 | 5 | 701de463f85aaad3a4b36a0d5fbc416406620089 | |
| ToppCell | PND14-Endothelial-Endothelial_blood-vessel-Microvascular_EC-EPC-EPC_prolif|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 5.22e-05 | 172 | 104 | 5 | 2b6cd84c946b1e800caba452ae70145ea285fec1 | |
| ToppCell | droplet-Liver-Hepatocytes-21m-Myeloid|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.22e-05 | 172 | 104 | 5 | 1627fa7035b0e0bbc82a1c0f000d8231254c680a | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic-Nonclassical_Monocyte-Mono_c5-CD16|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 5.66e-05 | 175 | 104 | 5 | dc7721794162dee96944f4b4b87b5681bb02ea8f | |
| ToppCell | droplet-Lung-nan-3m-Myeloid-Proliferating_Alveolar_Macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.14e-05 | 178 | 104 | 5 | de6cd81e6d58e7687386df163471bf1901b9c0aa | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_S-high|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 6.30e-05 | 179 | 104 | 5 | 80112c686a8f85ad5e3cda6e3f3d3d51cf688092 | |
| ToppCell | Control-Fibroblasts-Airway_smooth_muscle|Control / group, cell type (main and fine annotations) | 6.47e-05 | 180 | 104 | 5 | d0de12749ef0f51f0931c6e7b9b99966bdbc3ec1 | |
| ToppCell | facs-Liver-Hepatocytes-24m-Epithelial|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.82e-05 | 182 | 104 | 5 | 770ce9f3f4538d0181a0181543841bc964c68274 | |
| ToppCell | facs-Skin-Skin_Anagen-18m-Epithelial-actively_dividing_stem_cell|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.82e-05 | 182 | 104 | 5 | bc6a120dedc813c58baac1428c39851a07b71ba7 | |
| ToppCell | facs-Liver-Hepatocytes-24m-Epithelial-nan|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.82e-05 | 182 | 104 | 5 | 77ab860e2add49dad0c1ffbfc64278ad499dfbd5 | |
| ToppCell | facs-Skin-Skin_Anagen-18m-Epithelial-keratinocyte_stem_cell|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.82e-05 | 182 | 104 | 5 | 0fc45214f0b0766f69be6eff69cc4bec574023aa | |
| ToppCell | facs-Liver-Hepatocytes-24m-Epithelial-hepatocyte|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.82e-05 | 182 | 104 | 5 | 4921c7d5687cc79f896b39753bb621d7e3d2972f | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.18e-05 | 184 | 104 | 5 | 2cbed6462fea2622871bb7e49b0df3d984239281 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.18e-05 | 184 | 104 | 5 | ea7a7e2bac46d4d2c31a5d576b38a032b5335062 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.18e-05 | 184 | 104 | 5 | 2b19a8c5f823e00812908b23e66bb4e563278aff | |
| ToppCell | droplet-Lung-LUNG-30m-Myeloid-Proliferating_Alveolar_Macrophage|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.18e-05 | 184 | 104 | 5 | 16aa8e88bdd51b1d132d5cf33c29963b384a8bae | |
| ToppCell | droplet-Lung-30m-Hematologic-myeloid-alveolar_macrophage-proliferating_alveolar_macrophage|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 7.37e-05 | 185 | 104 | 5 | b4af9ae4c358b48357cb135b740266e1652d886a | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Myofibroblast|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 7.56e-05 | 186 | 104 | 5 | 6add08d4ca019ff2864acdd5ec2c66a59a574591 | |
| ToppCell | normal_Pleural_Fluid-Myeloid_cells-Alveolar_Mac|normal_Pleural_Fluid / Location, Cell class and cell subclass | 7.56e-05 | 186 | 104 | 5 | 3314def702fe6a5056d0dadbb3a587c5d1a16412 | |
| ToppCell | facs-Skin-Telogen-3m-Epithelial-actively_dividing_stem_cell|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.56e-05 | 186 | 104 | 5 | 9feef5936985e936b3d88f9d1bb012abb6468570 | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Myeloid-Mono-Mono_anti-infl-Z|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 7.56e-05 | 186 | 104 | 5 | f73cb91e74a806858650ae97f543fc779ba4cff8 | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Myeloid-Mono-Mono_anti-infl|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 7.56e-05 | 186 | 104 | 5 | 8694ca16c9780729f4fba67ba20e35745f1eb4e9 | |
| ToppCell | facs-Skin-Telogen-3m-Epithelial-keratinocyte_stem_cell|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.56e-05 | 186 | 104 | 5 | 89f5b06bc56674af304912d481ac697c7c870904 | |
| ToppCell | CF-Lymphoid-T_cell_&_NK_cell|Lymphoid / Disease state, Lineage and Cell class | 7.95e-05 | 188 | 104 | 5 | 15057036b46c9df621ec4955aa94ca3036245d45 | |
| ToppCell | COVID_vent-Myeloid-Monocytic-SC_&_Eosinophil|COVID_vent / Disease condition, Lineage, Cell class and subclass | 8.15e-05 | 189 | 104 | 5 | 2157a2d40613f7d5ce2e7dbd266df441e449cdaf | |
| ToppCell | 3'-Adult-LargeIntestine-Mesenchymal-myocytic|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 8.15e-05 | 189 | 104 | 5 | f7e2ee5047792ab9ef6472fa88e2d193cdea6fa0 | |
| ToppCell | PBMC-Mild-cDC_12|Mild / Compartment, Disease Groups and Clusters | 8.15e-05 | 189 | 104 | 5 | 946c95d2ecc36b241f58e8c4ad6455fe47c762fa | |
| ToppCell | facs-Skin-Skin_Anagen-18m-Epithelial-outer_bulge|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.15e-05 | 189 | 104 | 5 | d00410010283dc6191ce9857d6c7952678fed588 | |
| ToppCell | pdx-Tumor_cells-T8|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 8.35e-05 | 190 | 104 | 5 | b05db0de9b6ae01dd30074453f7de44f7397631e | |
| ToppCell | droplet-Lung-21m-Hematologic-lymphocytic-Proliferating_T_cell-proliferating_T|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 8.56e-05 | 191 | 104 | 5 | 15dbc5a03bfab8931c0fd385b0f25874736ae874 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c07-AHNAK|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 8.56e-05 | 191 | 104 | 5 | b53b490a8796e819edd3eb4a5a42b4499077b2d3 | |
| ToppCell | droplet-Lung-21m-Hematologic-lymphocytic-Proliferating_T_cell|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 8.56e-05 | 191 | 104 | 5 | 45c15f5ce4a207ac944bed65d45f06c1657d1a6d | |
| ToppCell | facs-Mammary_Gland-Mammary_Gland-21m-Epithelial-basal_cell|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.56e-05 | 191 | 104 | 5 | 2f733d510a4862565a817f59829d8387d7ea26d9 | |
| ToppCell | human_hepatoblastoma-Tumor_cells-T8|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 8.77e-05 | 192 | 104 | 5 | e785135262f4c9cc66c403bf362bb34643b212c5 | |
| ToppCell | 3'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophage_proliferating-|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 8.99e-05 | 193 | 104 | 5 | e45ce9cf8421512b57f157c24b64793b47b4ba4b | |
| ToppCell | Smart-start-Cell-Wel_seq-Neoplastic-Stem-like-NPC-like-NPC-like_neural-F|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 8.99e-05 | 193 | 104 | 5 | 088c8b1e968f5356502347eaabdc6b1b1d4befd0 | |
| ToppCell | Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 9.21e-05 | 194 | 104 | 5 | 97534c8bba895a7913665e03ae4e5c4a6ad71daf | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_S-high|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 9.21e-05 | 194 | 104 | 5 | 4c1d13d8cb6fb424655c67755ee6dbaf59d6b418 | |
| ToppCell | remission-CD4+_Tcm|World / disease stage, cell group and cell class | 9.44e-05 | 195 | 104 | 5 | 365a06e2fb48ec5262a4e2580ba5a592e48127e0 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_cycling-mes_proliferating1_(3)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 9.44e-05 | 195 | 104 | 5 | cec7df321f372d05c94f97d6bb18891a5cc3dec3 | |
| ToppCell | facs-Thymus-nan-3m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.44e-05 | 195 | 104 | 5 | 93c345e70d6c8ff5d12fd63d73228c1700b804a0 | |
| ToppCell | 3'-Distal_airway-Immune_Myeloid-Myeloid_macrophage|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.44e-05 | 195 | 104 | 5 | 9e49e59a20b1bbd6167d594c33ab6bdfe2c1ebaf | |
| ToppCell | 3'-Distal_airway-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.44e-05 | 195 | 104 | 5 | 412a9fcf9f075d97fae254bbd89774e4b1face07 | |
| ToppCell | hematopoetic_progenitors-CD34+_HSC|hematopoetic_progenitors / Lineage and Cell class | 9.67e-05 | 196 | 104 | 5 | d3e20212c15cff0a3c4e23e8b94715b5822a43e2 | |
| ToppCell | Tracheal-NucSeq-Epithelial-Epi_submucosal-gland-Myoepithelial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 9.90e-05 | 197 | 104 | 5 | f0475ad9c09c6da418dba17d3d3c1aaa2ef9ab4e | |
| ToppCell | Bronchial-NucSeq-Stromal-Peri/Epineurial_-NAF_epineurial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 9.90e-05 | 197 | 104 | 5 | dfeb4a0eb4dfba90f4a3e6ba31e0ab0e4aba5849 | |
| ToppCell | T_cells-CTLs|T_cells / Immune cells in Kidney/Urine in Lupus Nephritis | 9.90e-05 | 197 | 104 | 5 | 28117cf300e169182571fbad0de1681a484a435a | |
| ToppCell | Fibroblast|World / shred by cell class for bronchial biopsy | 9.90e-05 | 197 | 104 | 5 | 8bf9846228b6b6721b10375fe54a2fb389ff64a6 | |
| ToppCell | Tracheal-NucSeq-Stromal-Myofibroblastic-Muscle_smooth_pulmonary|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 9.90e-05 | 197 | 104 | 5 | ac4f53acb2f8a428b0f2fab3c30a34e095a1bed7 | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature-Organoid-2M-IPC_like|Organoid-2M / Sample Type, Dataset, Time_group, and Cell type. | 1.01e-04 | 198 | 104 | 5 | 6d12ecaa9532c134d9c4562534dcb59a6420b4d3 | |
| ToppCell | Transplant_Alveoli_and_parenchyma-Immune-Luminal_Macrophages|Immune / Tissue, Lineage and Cell class of Lung Cells from 10X | 1.01e-04 | 198 | 104 | 5 | 382ad6ebc6e0274ace361de72c0a3df05c846456 | |
| ToppCell | mild-Lymphocytic-NK_cells|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 1.01e-04 | 198 | 104 | 5 | dce3c008757786aa6bd4a869456b76b4cbbb1d5b | |
| ToppCell | COVID-19_Mild|World / Disease condition and Cell class | 1.01e-04 | 198 | 104 | 5 | 61ceb2245b6cb58e308b999a61d218c89dbc615e | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature-Organoid-2M-IPC_like-IPs_and_early_cortical_neurons|Organoid-2M / Sample Type, Dataset, Time_group, and Cell type. | 1.01e-04 | 198 | 104 | 5 | 7943e4f67c3d6efb5c8b00aa0ff3cfe7be10c48d | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic-Classical_Monocyte|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.01e-04 | 198 | 104 | 5 | 94e2567f057b2c455a9656b121321a28e7cb1d2b | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.01e-04 | 198 | 104 | 5 | f3a12a7e23bb4ff6e82fee675dbc090d99587f69 | |
| ToppCell | mLN-(5)_Dendritic_cell-(53)_Lymphoid_DC|mLN / shred on region, Cell_type, and subtype | 1.01e-04 | 198 | 104 | 5 | da84c76afe835aeee39da04b63c03549218b5d91 | |
| ToppCell | mLN-Dendritic_cell-Lymphoid_DC|mLN / Region, Cell class and subclass | 1.01e-04 | 198 | 104 | 5 | 3965a9f1e8a51a196e5349aaca5fa5ed1cd8ee92 | |
| ToppCell | Biopsy_Control_(H.)-Epithelial-Proliferating_Epithelial_cells|Biopsy_Control_(H.) / Sample group, Lineage and Cell type | 1.04e-04 | 199 | 104 | 5 | 4fcf5bec207e4384fd73c5e8801a7e414e3ee7b0 | |
| ToppCell | BAL-Control-cDC_0|Control / Compartment, Disease Groups and Clusters | 1.04e-04 | 199 | 104 | 5 | 4518ffa51ead9da1ddf07bf048b18602e50f0f84 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic-Classical_Monocyte-Mono_c2-CD14-HLA-DPB1|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.04e-04 | 199 | 104 | 5 | 97af159fa3a5533ec3d45331fb80c6da8a715aa5 | |
| ToppCell | Tracheal-NucSeq-Stromal-Peri/Epineurial_-NAF_epineurial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.04e-04 | 199 | 104 | 5 | 9c2db0bb94cba71a3cc1827844da090e213e0258 | |
| ToppCell | LPS_IL1RA-Endothelial-Endothelial-Gen_Cap|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 1.06e-04 | 200 | 104 | 5 | dccec522ab0d7fff62ad6273b02aa9022dbbb8eb | |
| ToppCell | 390C-Endothelial_cells-Endothelial-B_(Artery)-|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 1.06e-04 | 200 | 104 | 5 | c32ad15dede3f879007c0b856f2fed1f5b058103 | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-3m-Stem_cells-Neuroepithelial_cell|3m / Sample Type, Dataset, Time_group, and Cell type. | 1.06e-04 | 200 | 104 | 5 | 2938a029fa0478be561574ace91f95c4a528b2d4 | |
| ToppCell | Control_saline-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|Control_saline / Treatment groups by lineage, cell group, cell type | 1.06e-04 | 200 | 104 | 5 | c5e051f1aac8dda376c342a9932785a23450e073 | |
| ToppCell | Fetal_brain-fetalBrain_Zhong_nature-GW10-Stem_cells|GW10 / Sample Type, Dataset, Time_group, and Cell type. | 1.06e-04 | 200 | 104 | 5 | 474e6ab48f199315f3cca86b81fdf54e0461b7b8 | |
| ToppCell | Control_saline-Endothelial-Endothelial-Gen_Cap|Control_saline / Treatment groups by lineage, cell group, cell type | 1.06e-04 | 200 | 104 | 5 | 3b97920e1e6e2f09ddba2a861baa9c00c2970f4c | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_myocytic-Pericyte-Pericyte_3|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.06e-04 | 200 | 104 | 5 | c06426f877919bdd267ea2fd7e7973c6619832ae | |
| ToppCell | Control_saline-Mesenchymal_myocytic|Control_saline / Treatment groups by lineage, cell group, cell type | 1.06e-04 | 200 | 104 | 5 | 5ed4261157cd51109b314818133ac3a0d34ee5fa | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-3m-Stem_cells|3m / Sample Type, Dataset, Time_group, and Cell type. | 1.06e-04 | 200 | 104 | 5 | cfe017b4a4d604a553d0a3df9659687f38e9a7af | |
| ToppCell | LPS_anti-TNF-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 1.06e-04 | 200 | 104 | 5 | c596a53c0b63c9deaac7d99fcbdd94ecfa96b86c | |
| ToppCell | Neuronal-Inhibitory-iA|Neuronal / cells hierarchy compared to all cells using T-Statistic | 1.06e-04 | 200 | 104 | 5 | 5ef4a3dc18a44292184a59ced916183c0699b01e | |
| ToppCell | Sepsis-Bac-SEP-Lymphocyte-T/NK-T/NK_proliferative|Bac-SEP / Disease, condition lineage and cell class | 1.06e-04 | 200 | 104 | 5 | a09b4e07b273880e94032b939ab191caaf6d656e | |
| ToppCell | LPS_only-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|LPS_only / Treatment groups by lineage, cell group, cell type | 1.06e-04 | 200 | 104 | 5 | 593bf6a7c557437db9a9249a5058a46014179ef6 | |
| ToppCell | LPS_only-Mesenchymal_myocytic-Myofibroblastic|LPS_only / Treatment groups by lineage, cell group, cell type | 1.06e-04 | 200 | 104 | 5 | 02cae2c296a13ad4cbb53bca7a86d64629d67d66 | |
| ToppCell | Tracheal-10x5prime-Stromal-Fibroblastic-Fibro_adventitial|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.06e-04 | 200 | 104 | 5 | 74ad0ae592252060ee294d7483327d765a6ba1dd | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 1.06e-04 | 200 | 104 | 5 | dcdaec3ca3a3024dc1b8788c417003f84c2bffdc | |
| ToppCell | 390C-Endothelial_cells-Endothelial-B_(Artery)|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 1.06e-04 | 200 | 104 | 5 | 8a2c6c53a39fab86750526083f7254b7413b29af | |
| ToppCell | Tracheal-10x5prime-Stromal-Fibroblastic|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.06e-04 | 200 | 104 | 5 | 7ba292c30d915e66ebc8026fa76492cedf64700e | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-6m-Neuronal-Neuron|6m / Sample Type, Dataset, Time_group, and Cell type. | 1.06e-04 | 200 | 104 | 5 | b5019b9d48f32cffd4645a5c0f3e0ac504ea8019 | |
| ToppCell | Fetal_brain-fetalBrain_Zhong_nature-GW10-Stem_cells-Stem_cells|GW10 / Sample Type, Dataset, Time_group, and Cell type. | 1.06e-04 | 200 | 104 | 5 | 01a29651e9bb64ef7666c6a61ec396eeb88b2816 | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW12|organoid_Tanaka_cellReport / Sample Type, Dataset, Time_group, and Cell type. | 1.06e-04 | 200 | 104 | 5 | 2d167b6e3f4b47e537b2e5b9b2f104f80573970b | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c09-GZMK-FOS_l|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.38e-04 | 129 | 104 | 4 | a60935ff9c5a841899ccfe90531533ba4c546df3 | |
| ToppCell | TCGA-Bladder-Primary_Tumor-Urothelial_Carcinoma-Papillary_Muscle_Invasive_Urothelial_Carcinoma-8|TCGA-Bladder / Sample_Type by Project: Shred V9 | 4.11e-04 | 149 | 104 | 4 | 89705865e94360c1288ee98c5a6b381f3c6242b3 | |
| ToppCell | droplet-Liver-nan-3m-Epithelial-Hepatocyte_(Pericentral,_Midlobular,_Periportal)|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.32e-04 | 151 | 104 | 4 | cc9632b58522e2ba3ad36a0b8d37c7c9c8b636c4 | |
| ToppCell | droplet-Liver-nan-3m-Epithelial|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.32e-04 | 151 | 104 | 4 | 7758cfbe8dca849c90bd6e8bc63310e53beeb8fd | |
| ToppCell | droplet-Liver-nan-3m-Epithelial-hepatocyte|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.32e-04 | 151 | 104 | 4 | b4a0546c1573b4b2290890307f2a5daf3a7cbb37 | |
| Computational | Genes in the cancer module 303. | 2.66e-08 | 28 | 73 | 6 | MODULE_303 | |
| Drug | flavopiridol | 5.76e-08 | 216 | 104 | 10 | CID005287969 | |
| Drug | Hymenialdisine | 9.26e-08 | 3 | 104 | 3 | DB02950 | |
| Drug | SU9516 | 9.26e-08 | 3 | 104 | 3 | DB03428 | |
| Drug | manganese | DPYD NPR3 NMNAT1 IREB2 CPS1 ADCY2 PHKA1 LIG3 NUDT11 CSNK1A1L CSNK1A1 SLC25A2 NUDT10 AKT1 HAGH ENO2 CDK2 | 1.07e-07 | 791 | 104 | 17 | CID000023930 |
| Drug | NG97 | 2.35e-07 | 30 | 104 | 5 | CID006604931 | |
| Drug | Gallic Acid | 3.10e-07 | 97 | 104 | 7 | ctd:D005707 | |
| Drug | Alsterpaullone | 3.69e-07 | 4 | 104 | 3 | DB04014 | |
| Drug | Olomoucine | 3.69e-07 | 4 | 104 | 3 | DB02116 | |
| Drug | Indirubin-3'-Monoxime | 3.69e-07 | 4 | 104 | 3 | DB02052 | |
| Drug | Simvastatin | SLC38A4 APOB FASLG LDLR CHUK SGK2 ABCG1 CAMKK2 TIMP2 AKT1 CDK1 VDAC1 CDK2 CDK5 | 4.10e-07 | 581 | 104 | 14 | ctd:D019821 |
| Drug | 2c5o | 7.24e-07 | 284 | 104 | 10 | CID000447956 | |
| Drug | NSC105327 | 8.12e-07 | 70 | 104 | 6 | CID005318433 | |
| Drug | Curcumin | SRC APC FASLG LDLR CHUK LIG3 ABCG1 PTPN13 NOD1 TIMP2 FANCI AKT1 CDK1 CDK2 CDK5 DNMT3B | 1.52e-06 | 850 | 104 | 16 | ctd:D003474 |
| Drug | AC1L1IL4 | 1.83e-06 | 6 | 104 | 3 | CID000004625 | |
| Drug | PD179483 | 1.83e-06 | 6 | 104 | 3 | CID005330526 | |
| Drug | Coralyne chloride hydrate [38989-38-7]; Up 200; 9.6uM; MCF7; HT_HG-U133A | 3.08e-06 | 194 | 104 | 8 | 5418_UP | |
| Drug | GW8510 | 3.20e-06 | 7 | 104 | 3 | CID005353653 | |
| Drug | Sulindac [38194-50-2]; Up 200; 11.2uM; HL60; HT_HG-U133A | 3.20e-06 | 195 | 104 | 8 | 1857_UP | |
| Drug | amitriptyline hydrochloride; Down 200; 1uM; MCF7; HG-U133A | 3.32e-06 | 196 | 104 | 8 | 167_DN | |
| Drug | wortmannin | 3.81e-06 | 267 | 104 | 9 | ctd:C009687 | |
| Drug | procarbazine | 4.34e-06 | 93 | 104 | 6 | CID000004915 | |
| Drug | 3'-Me-DAB | 4.78e-06 | 54 | 104 | 5 | CID000005934 | |
| Drug | 3-deazacytidine | 4.80e-06 | 206 | 104 | 8 | CID000001652 | |
| Drug | AG-012986 | 5.10e-06 | 8 | 104 | 3 | ctd:C512484 | |
| Drug | NU2058 | 5.10e-06 | 8 | 104 | 3 | CID000004564 | |
| Drug | NSC281245 | 5.22e-06 | 96 | 104 | 6 | CID000002854 | |
| Drug | sulfonamide analog 1 | 6.14e-06 | 213 | 104 | 8 | CID005327336 | |
| Drug | CVT-313 | 7.62e-06 | 9 | 104 | 3 | CID006918386 | |
| Drug | sorafenib | 8.20e-06 | 158 | 104 | 7 | CID000216239 | |
| Drug | 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline | 8.94e-06 | 29 | 104 | 4 | ctd:C568862 | |
| Drug | 4-(hydroxyamino)quinoline 1-oxide | 1.09e-05 | 10 | 104 | 3 | CID000020753 | |
| Drug | Flavopiridol | 1.09e-05 | 10 | 104 | 3 | DB03496 | |
| Drug | HAVA | 1.09e-05 | 10 | 104 | 3 | CID000170929 | |
| Drug | NSC683246 | 1.22e-05 | 234 | 104 | 8 | CID000005097 | |
| Drug | BIRB796 | 1.29e-05 | 66 | 104 | 5 | CID000156422 | |
| Drug | guanine | NPR3 BRIP1 NMNAT1 SYNM ITGB1BP1 SRC APC GMPR2 ADCY2 LDLR TUFM CASK NUDT10 AKT1 PLCB3 | 1.47e-05 | 902 | 104 | 15 | CID000000764 |
| Drug | sodium tetradecyl sulphate | 1.49e-05 | 11 | 104 | 3 | CID000005248 | |
| Drug | pyrazolanthrone | 1.71e-05 | 322 | 104 | 9 | ctd:C432165 | |
| Drug | AR-A014418 | 1.93e-05 | 35 | 104 | 4 | CID000448014 | |
| Drug | adenosine 5'-tetraphosphate | 2.07e-05 | 2 | 104 | 2 | ctd:C017991 | |
| Drug | AC1O5R58 | 2.07e-05 | 2 | 104 | 2 | CID006439178 | |
| Drug | diadenosine 5',5''''-P1,P6-hexaphosphate | 2.07e-05 | 2 | 104 | 2 | ctd:C070070 | |
| Drug | BMS-265246 | 2.07e-05 | 2 | 104 | 2 | CID005329775 | |
| Drug | SQ-67563 | 2.07e-05 | 2 | 104 | 2 | CID005329767 | |
| Drug | adenosine 5'-pentaphosphate | 2.07e-05 | 2 | 104 | 2 | ctd:C048567 | |
| Drug | candesartan | 2.26e-05 | 74 | 104 | 5 | ctd:C081643 | |
| Drug | orotic acid | 2.27e-05 | 124 | 104 | 6 | CID000000967 | |
| Drug | Trichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A | 2.28e-05 | 185 | 104 | 7 | 2949_UP | |
| Drug | Diethylstilbestrol | CDK16 HSPE1 NRIP1 DPYD SLC38A4 SRC DCC FASLG CHUK PIK3IP1 KMT2C NALCN AKT1 CDK1 ENO2 CDK2 CDK5 DNMT3B | 2.39e-05 | 1305 | 104 | 18 | ctd:D004054 |
| Drug | aloisine A | 2.56e-05 | 13 | 104 | 3 | CID005326843 | |
| Drug | 3-isoreserpine | 2.71e-05 | 190 | 104 | 7 | CID000005052 | |
| Drug | butyrolactone I | 2.71e-05 | 128 | 104 | 6 | CID000123740 | |
| Drug | AC1L1IHP | SRC IREB2 APOB CHUK PHKA1 PTPN13 CSNK1A1L CSNK1A1 AKT1 PLCB3 CDK1 CDK2 CDK5 | 2.76e-05 | 728 | 104 | 13 | CID000004584 |
| Drug | SC 19220; Down 200; 10uM; PC3; HT_HG-U133A | 2.90e-05 | 192 | 104 | 7 | 7065_DN | |
| Drug | pterostilbene | 2.96e-05 | 130 | 104 | 6 | ctd:C107773 | |
| Drug | Ascorbic Acid | HSPE1 SRC DAB2 IREB2 APOB FAT1 GLA RAD54B AKT1 CDK1 VDAC1 CDK2 | 2.99e-05 | 628 | 104 | 12 | ctd:D001205 |
| Drug | Cinchonine [118-10-5]; Down 200; 13.6uM; MCF7; HT_HG-U133A | 3.10e-05 | 194 | 104 | 7 | 4107_DN | |
| Drug | Resveratrol [501-36-0]; Up 200; 17.6uM; MCF7; HT_HG-U133A | 3.20e-05 | 195 | 104 | 7 | 2865_UP | |
| Drug | olomoucine | 3.23e-05 | 132 | 104 | 6 | CID000004592 | |
| Drug | 7-benzylamino-5-(2-(hydroxymethyl)propyl)amino-3-isopropyl-1(2)H-pyrazolo(4,3-d)pyrimidine | 3.25e-05 | 14 | 104 | 3 | ctd:C559145 | |
| Drug | H-89, Dihydrochloride; Down 200; 0.5uM; PC3; HT_HG-U133A | 3.30e-05 | 196 | 104 | 7 | 6873_DN | |
| Drug | Bretylium tosylate [61-75-6]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 3.30e-05 | 196 | 104 | 7 | 5020_DN | |
| Drug | roscovitine | 3.31e-05 | 40 | 104 | 4 | ctd:C104586 | |
| Drug | docetaxel | 3.37e-05 | 133 | 104 | 6 | ctd:C067311 | |
| Drug | S-(+)-ibuprofen [51146-56-6]; Up 200; 19.4uM; MCF7; HT_HG-U133A | 3.41e-05 | 197 | 104 | 7 | 6471_UP | |
| Drug | Sulindac [38194-50-2]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 3.41e-05 | 197 | 104 | 7 | 1693_DN | |
| Drug | NSC302991 | 3.52e-05 | 353 | 104 | 9 | CID000002538 | |
| Drug | Aztreonam [78110-38-0]; Up 200; 9.2uM; PC3; HT_HG-U133A | 3.53e-05 | 198 | 104 | 7 | 2118_UP | |
| Drug | Dihydroergotoxine mesylate [8067-24-1]; Up 200; 6.4uM; PC3; HT_HG-U133A | 3.53e-05 | 198 | 104 | 7 | 4071_UP | |
| Drug | Pramoxine hydrochloride [637-58-1]; Up 200; 12.2uM; HL60; HT_HG-U133A | 3.64e-05 | 199 | 104 | 7 | 2198_UP | |
| Drug | Oxalamine citrate salt [1949-20-8]; Down 200; 9.2uM; PC3; HT_HG-U133A | 3.64e-05 | 199 | 104 | 7 | 6624_DN | |
| Drug | Dehydroisoandosterone 3-acetate [853-23-6]; Down 200; 12.2uM; HL60; HT_HG-U133A | 3.76e-05 | 200 | 104 | 7 | 3097_DN | |
| Drug | farnesylthiosalicylic acid | 4.05e-05 | 15 | 104 | 3 | ctd:C093323 | |
| Drug | AC1L1GFH | 4.42e-05 | 43 | 104 | 4 | CID000003660 | |
| Drug | kenpaullone | 4.42e-05 | 43 | 104 | 4 | CID000003820 | |
| Drug | Cgp77675 | 4.42e-05 | 43 | 104 | 4 | CID005311381 | |
| Drug | AC1LD8Z3 | 4.69e-05 | 86 | 104 | 5 | CID000644309 | |
| Drug | EKB-569 | 4.95e-05 | 87 | 104 | 5 | CID006445562 | |
| Drug | CK2 inhibitor | 4.95e-05 | 87 | 104 | 5 | CID000001694 | |
| Drug | PD166326 | 4.97e-05 | 16 | 104 | 3 | CID000447700 | |
| Drug | emopamil | 4.97e-05 | 16 | 104 | 3 | CID000071225 | |
| Drug | Lovastatin | 5.28e-05 | 211 | 104 | 7 | ctd:D008148 | |
| Drug | AC1L4MJU | 5.36e-05 | 288 | 104 | 8 | CID000159822 | |
| Drug | NSC406942 | HSPE1 SYNM APOB ADCY2 TUFM CSNK1A1L GLA NUAK1 CSNK1A1 RPL3 VDAC1 | 5.53e-05 | 565 | 104 | 11 | CID000001115 |
| Drug | ezetimibe | 5.90e-05 | 147 | 104 | 6 | CID000150311 | |
| Drug | AC1MU1S9 | FLNA DPYD NPR3 SRC FASLG LDLR C3orf33 CAMKK2 PIK3C2B AKT1 PLCB3 | 6.18e-05 | 572 | 104 | 11 | CID000003733 |
| Drug | AC1LCV2J | 6.18e-05 | 3 | 104 | 2 | CID000656488 | |
| Drug | CDK1 inhibitor III | 6.18e-05 | 3 | 104 | 2 | CID000403994 | |
| Drug | pirozadil | 6.18e-05 | 3 | 104 | 2 | CID000068711 | |
| Drug | adenosine 3',5'-cyclic phosphate | NPR3 SYNM CPS1 DCC ADCY2 LDLR PHKA1 CAMKK2 CSNK1A1L CSNK1A1 AKT1 PLCB3 CDK1 CDK2 | 6.51e-05 | 907 | 104 | 14 | CID000000274 |
| Drug | Filipin | 7.19e-05 | 18 | 104 | 3 | ctd:D005372 | |
| Drug | racer | 7.19e-05 | 18 | 104 | 3 | CID000091677 | |
| Drug | naphtho(1,2-b)furan-4,5-dione | 7.19e-05 | 18 | 104 | 3 | ctd:C073873 | |
| Drug | NSC-364372 | 7.53e-05 | 484 | 104 | 10 | CID000435143 | |
| Drug | 1-methylcyclopentanecarboxylic acid | 7.55e-05 | 95 | 104 | 5 | CID000138436 | |
| Drug | UCN-01 | 7.64e-05 | 154 | 104 | 6 | CID000072271 | |
| Drug | Drugs, Chinese Herbal | 7.67e-05 | 586 | 104 | 11 | ctd:D004365 | |
| Drug | Capsaicin | 8.06e-05 | 488 | 104 | 10 | ctd:D002211 | |
| Drug | nickel chloride | HSPE1 TES NMNAT1 DAB2 APC LDLR CHUK PIK3IP1 ABCG1 NOD1 GLA AKT1 ENO2 RPL3 CDK5 PDZD2 | 8.59e-05 | 1178 | 104 | 16 | ctd:C022838 |
| Drug | NSC618487 | CDK16 NPR3 SRC APOB CHUK CAMKK2 PTPN13 EFNB1 AKT1 PLCB3 CDK1 VDAC1 CDK2 CDK5 | 8.80e-05 | 933 | 104 | 14 | CID000005279 |
| Disease | colorectal cancer (is_implicated_in) | 1.17e-08 | 121 | 104 | 8 | DOID:9256 (is_implicated_in) | |
| Disease | Colorectal cancer | 3.75e-08 | 27 | 104 | 5 | cv:C0346629 | |
| Disease | COLORECTAL CANCER | 3.75e-08 | 27 | 104 | 5 | 114500 | |
| Disease | Neoplasm of the large intestine | 3.75e-08 | 27 | 104 | 5 | cv:C0009404 | |
| Disease | prostate cancer (is_implicated_in) | 1.99e-07 | 117 | 104 | 7 | DOID:10283 (is_implicated_in) | |
| Disease | Colorectal Neoplasms | 6.45e-06 | 277 | 104 | 8 | C0009404 | |
| Disease | Colorectal Carcinoma | DPYD SRC APC APOB DCC KMT2C LIG3 ABCG1 FAT1 CSNK1A1L ABCA6 AKT1 | 7.03e-06 | 702 | 104 | 12 | C0009402 |
| Disease | low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio | 7.21e-06 | 200 | 104 | 7 | EFO_0004611, EFO_0020945 | |
| Disease | Malignant Head and Neck Neoplasm | 1.77e-05 | 44 | 104 | 4 | C0278996 | |
| Disease | Lipidemias | 2.79e-05 | 17 | 104 | 3 | C1706412 | |
| Disease | Hyperlipidemia | 2.79e-05 | 17 | 104 | 3 | C0020473 | |
| Disease | FG syndrome (is_implicated_in) | 3.68e-05 | 3 | 104 | 2 | DOID:14711 (is_implicated_in) | |
| Disease | FG SYNDROME 4 (disorder) | 3.68e-05 | 3 | 104 | 2 | C1845546 | |
| Disease | FG SYNDROME 2 | 3.68e-05 | 3 | 104 | 2 | C1845902 | |
| Disease | FG SYNDROME 3 | 3.68e-05 | 3 | 104 | 2 | C1845567 | |
| Disease | FG syndrome | 3.68e-05 | 3 | 104 | 2 | C0220769 | |
| Disease | Glioblastoma Multiforme | 4.70e-05 | 111 | 104 | 5 | C1621958 | |
| Disease | lipoprotein A measurement | 4.91e-05 | 112 | 104 | 5 | EFO_0006925 | |
| Disease | pancreatic cancer (is_implicated_in) | 4.91e-05 | 112 | 104 | 5 | DOID:1793 (is_implicated_in) | |
| Disease | triglycerides to total lipids in small LDL percentage | 5.71e-05 | 59 | 104 | 4 | EFO_0022337 | |
| Disease | FG syndrome | 7.35e-05 | 4 | 104 | 2 | cv:C0220769 | |
| Disease | Parkinson's disease (is_marker_for) | 9.41e-05 | 67 | 104 | 4 | DOID:14330 (is_marker_for) | |
| Disease | free cholesterol measurement, very low density lipoprotein cholesterol measurement | 1.17e-04 | 215 | 104 | 6 | EFO_0008317, EFO_0008591 | |
| Disease | thrombocytopenia (is_implicated_in) | 1.17e-04 | 27 | 104 | 3 | DOID:1588 (is_implicated_in) | |
| Disease | type 1 diabetes mellitus (is_marker_for) | 1.25e-04 | 72 | 104 | 4 | DOID:9744 (is_marker_for) | |
| Disease | very low density lipoprotein cholesterol measurement, lipid measurement | 1.33e-04 | 220 | 104 | 6 | EFO_0004529, EFO_0008317 | |
| Disease | colorectal cancer (implicated_via_orthology) | 1.61e-04 | 30 | 104 | 3 | DOID:9256 (implicated_via_orthology) | |
| Disease | very low density lipoprotein cholesterol measurement, phospholipid measurement | 1.65e-04 | 229 | 104 | 6 | EFO_0004639, EFO_0008317 | |
| Disease | triglycerides:total lipids ratio, low density lipoprotein cholesterol measurement | 1.95e-04 | 150 | 104 | 5 | EFO_0004611, EFO_0020947 | |
| Disease | Epilepsy, Cryptogenic | 2.06e-04 | 82 | 104 | 4 | C0086237 | |
| Disease | Awakening Epilepsy | 2.06e-04 | 82 | 104 | 4 | C0751111 | |
| Disease | Aura | 2.06e-04 | 82 | 104 | 4 | C0236018 | |
| Disease | LDL cholesterol change measurement | 2.55e-04 | 7 | 104 | 2 | EFO_0007804 | |
| Disease | liver disease (biomarker_via_orthology) | 2.55e-04 | 7 | 104 | 2 | DOID:409 (biomarker_via_orthology) | |
| Disease | syndromic X-linked intellectual disability Najm type (implicated_via_orthology) | 2.55e-04 | 7 | 104 | 2 | DOID:0060807 (implicated_via_orthology) | |
| Disease | colon cancer (is_implicated_in) | 2.79e-04 | 36 | 104 | 3 | DOID:219 (is_implicated_in) | |
| Disease | Schizophrenia | 2.87e-04 | 883 | 104 | 11 | C0036341 | |
| Disease | free cholesterol to total lipids in large VLDL percentage | 3.03e-04 | 37 | 104 | 3 | EFO_0022281 | |
| Disease | very low density lipoprotein cholesterol measurement | 3.26e-04 | 260 | 104 | 6 | EFO_0008317 | |
| Disease | Familial hypercholesterolemia | 3.40e-04 | 8 | 104 | 2 | cv:C0020445 | |
| Disease | triglycerides to total lipids in large VLDL percentage | 3.54e-04 | 39 | 104 | 3 | EFO_0022332 | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement, lipid measurement | 3.62e-04 | 95 | 104 | 4 | EFO_0004529, EFO_0008317, EFO_0008596 | |
| Disease | Leukemia, Myelocytic, Acute | 3.76e-04 | 173 | 104 | 5 | C0023467 | |
| Disease | chylomicron measurement, triglyceride measurement, very low density lipoprotein cholesterol measurement | 3.77e-04 | 96 | 104 | 4 | EFO_0004530, EFO_0008317, EFO_0008596 | |
| Disease | Adenocarcinoma of large intestine | 3.77e-04 | 96 | 104 | 4 | C1319315 | |
| Disease | cholesterol in very small VLDL measurement | 3.82e-04 | 40 | 104 | 3 | EFO_0022231 | |
| Disease | free cholesterol in medium LDL measurement | 3.82e-04 | 40 | 104 | 3 | EFO_0022268 | |
| Disease | Colon Carcinoma | 4.36e-04 | 9 | 104 | 2 | C0699790 | |
| Disease | gastroesophageal reflux disease | 4.57e-04 | 101 | 104 | 4 | EFO_0003948 | |
| Disease | free cholesterol to total lipids in very small VLDL percentage | 4.74e-04 | 43 | 104 | 3 | EFO_0022290 | |
| Disease | cholesteryl esters:total lipids ratio, intermediate density lipoprotein measurement | 4.93e-04 | 103 | 104 | 4 | EFO_0008595, EFO_0020944 | |
| Disease | concentration of large LDL particles measurement | 5.07e-04 | 44 | 104 | 3 | EFO_0022160 | |
| Disease | cholesterol in medium VLDL measurement | 5.07e-04 | 44 | 104 | 3 | EFO_0022225 | |
| Disease | total lipids in very small VLDL measurement | 5.42e-04 | 45 | 104 | 3 | EFO_0022156 | |
| Disease | esophagus squamous cell carcinoma (is_implicated_in) | 5.42e-04 | 45 | 104 | 3 | DOID:3748 (is_implicated_in) | |
| Disease | cholesterol to total lipids in large VLDL percentage | 5.42e-04 | 45 | 104 | 3 | EFO_0022236 | |
| Disease | familial hypercholesterolemia (is_implicated_in) | 5.44e-04 | 10 | 104 | 2 | DOID:13810 (is_implicated_in) | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement | 5.49e-04 | 106 | 104 | 4 | EFO_0008317, EFO_0008596 | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement, phospholipid measurement | 6.10e-04 | 109 | 104 | 4 | EFO_0004639, EFO_0008317, EFO_0008596 | |
| Disease | Epilepsy | 6.10e-04 | 109 | 104 | 4 | C0014544 | |
| Disease | total lipids in small LDL | 6.16e-04 | 47 | 104 | 3 | EFO_0022168 | |
| Disease | free cholesterol in small VLDL measurement | 6.16e-04 | 47 | 104 | 3 | EFO_0022272 | |
| Disease | free cholesterol in very small VLDL measurement | 6.16e-04 | 47 | 104 | 3 | EFO_0022275 | |
| Disease | free cholesterol in medium VLDL measurement | 6.16e-04 | 47 | 104 | 3 | EFO_0022269 | |
| Disease | cholesteryl ester measurement, chylomicron measurement, very low density lipoprotein cholesterol measurement | 6.31e-04 | 110 | 104 | 4 | EFO_0008317, EFO_0008596, EFO_0010351 | |
| Disease | free cholesterol measurement, chylomicron measurement, very low density lipoprotein cholesterol measurement | 6.31e-04 | 110 | 104 | 4 | EFO_0008317, EFO_0008591, EFO_0008596 | |
| Disease | chylomicron measurement, total cholesterol measurement, very low density lipoprotein cholesterol measurement | 6.31e-04 | 110 | 104 | 4 | EFO_0004574, EFO_0008317, EFO_0008596 | |
| Disease | lung adenocarcinoma (is_implicated_in) | 6.97e-04 | 49 | 104 | 3 | DOID:3910 (is_implicated_in) | |
| Disease | phospholipids in medium LDL measurement | 6.97e-04 | 49 | 104 | 3 | EFO_0022183 | |
| Disease | apolipoprotein B to apolipoprotein A1 ratio | 6.97e-04 | 49 | 104 | 3 | EFO_0021897 | |
| Disease | cholesterol in medium LDL measurement | 6.97e-04 | 49 | 104 | 3 | EFO_0022224 | |
| Disease | cholesterol in small LDL measurement | 6.97e-04 | 49 | 104 | 3 | EFO_0022227 | |
| Disease | cholesteryl esters to total lipids in small VLDL percentage | 6.97e-04 | 49 | 104 | 3 | EFO_0022256 | |
| Disease | hepatocellular carcinoma (is_marker_for) | 7.05e-04 | 301 | 104 | 6 | DOID:684 (is_marker_for) | |
| Disease | free cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement | 7.29e-04 | 303 | 104 | 6 | EFO_0004612, EFO_0020945 | |
| Disease | triglycerides to total lipids in medium LDL percentage | 7.39e-04 | 50 | 104 | 3 | EFO_0022334 | |
| Disease | free cholesterol in LDL measurement | 7.39e-04 | 50 | 104 | 3 | EFO_0022266 | |
| Disease | phospholipids:total lipids ratio, high density lipoprotein cholesterol measurement | 7.81e-04 | 307 | 104 | 6 | EFO_0004612, EFO_0020946 | |
| Disease | free cholesterol in large LDL measurement | 7.83e-04 | 51 | 104 | 3 | EFO_0022176 | |
| Disease | phospholipids in very small VLDL measurement | 7.83e-04 | 51 | 104 | 3 | EFO_0022300 | |
| Disease | free cholesterol to total lipids in small HDL percentage | 7.83e-04 | 51 | 104 | 3 | EFO_0022285 | |
| Disease | phospholipids in medium VLDL measurement | 8.29e-04 | 52 | 104 | 3 | EFO_0022154 | |
| Disease | phospholipids in IDL measurement | 8.29e-04 | 52 | 104 | 3 | EFO_0022164 | |
| Disease | total lipids in medium LDL | 8.29e-04 | 52 | 104 | 3 | EFO_0022180 | |
| Disease | total lipids in LDL measurement | 8.29e-04 | 52 | 104 | 3 | EFO_0022308 | |
| Disease | phospholipids in large LDL measurement | 8.77e-04 | 53 | 104 | 3 | EFO_0022174 | |
| Disease | triglycerides to total lipids in very large VLDL percentage | 8.77e-04 | 53 | 104 | 3 | EFO_0022340 | |
| Disease | cholesterol in small VLDL measurement | 8.77e-04 | 53 | 104 | 3 | EFO_0022228 | |
| Disease | free cholesterol in small LDL measurement | 8.77e-04 | 53 | 104 | 3 | EFO_0022271 | |
| Disease | cholesteryl esters to total lipids in very large VLDL percentage | 8.77e-04 | 53 | 104 | 3 | EFO_0022258 | |
| Disease | cholesterol:total lipids ratio, intermediate density lipoprotein measurement | 9.02e-04 | 121 | 104 | 4 | EFO_0008595, EFO_0020943 | |
| Disease | cholesterol to total lipids in very large VLDL percentage | 9.26e-04 | 54 | 104 | 3 | EFO_0022244 | |
| Disease | Hyperlipoproteinemia Type IIb | 9.36e-04 | 13 | 104 | 2 | C1704417 | |
| Disease | gallbladder cancer (is_implicated_in) | 9.36e-04 | 13 | 104 | 2 | DOID:3121 (is_implicated_in) | |
| Disease | non-high density lipoprotein cholesterol measurement | 9.53e-04 | 713 | 104 | 9 | EFO_0005689 | |
| Disease | free cholesterol to total lipids in large HDL percentage | 1.03e-03 | 56 | 104 | 3 | EFO_0022279 | |
| Disease | cholesteryl esters to total lipids in large VLDL percentage | 1.03e-03 | 56 | 104 | 3 | EFO_0022250 | |
| Disease | triglycerides:total lipids ratio, intermediate density lipoprotein measurement | 1.08e-03 | 127 | 104 | 4 | EFO_0008595, EFO_0020947 | |
| Disease | total lipids in large LDL | 1.08e-03 | 57 | 104 | 3 | EFO_0022163 | |
| Disease | cholesterol in large LDL measurement | 1.08e-03 | 57 | 104 | 3 | EFO_0021901 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| GLIQKYKTGKGLFID | 226 | Q9HAC7 | |
| GYGFGLIKLDLKTKS | 21 | P21796 | |
| EYLKLLGKGTFGKVI | 151 | P31749 | |
| DKLGIYVKSVVKGGA | 1031 | P55196 | |
| LGGLVKGKSDPYVKL | 666 | Q9BSJ8 | |
| DLQGKDTYLKGLVKG | 396 | A0FGR8 | |
| AIVIKAGGRYLGKKV | 146 | P55199 | |
| KILKEKGYATGLIGK | 131 | P51690 | |
| TGYLVLKELGIKVGK | 586 | Q9UBC3 | |
| LIGLLYLGIGNEAKK | 436 | P45844 | |
| EGKVNKGIYLKEEKG | 66 | Q6QNK2 | |
| KLEKIGEGTYGTVFK | 6 | Q00535 | |
| IGFGKLETYVKLDKL | 136 | Q07002 | |
| LGQKGGKLYAVKVVK | 51 | Q96GX5 | |
| EYKGKSGKVEALKGL | 486 | Q8N139 | |
| KVGDKVLLPEYGGTK | 66 | P61604 | |
| SKGLKLGIYADVGNK | 126 | P06280 | |
| LKEKGYKAAFIGIGL | 271 | Q12882 | |
| DGDKQRYLGKGVLKA | 51 | P09104 | |
| KIPGKSGLYALKKEE | 71 | Q9C0F0 | |
| LGRYVGKDYKEQKGL | 1061 | Q96QP1 | |
| GEYKKTLLKLSGGDD | 311 | P08133 | |
| LRAGYSKKDGGKIIQ | 376 | P17342 | |
| LGQGKGEAKLDLKYV | 301 | Q5JR59 | |
| VYEEAGVKGKLGRLL | 66 | Q8NFP7 | |
| GKDIGRGIGYKFKEL | 161 | Q9Y620 | |
| IIKNKVTGESKGLGY | 151 | Q8IUH3 | |
| KEGIPLIILAGKKYG | 836 | P48200 | |
| DGVKYKAKLIGIDDV | 46 | P98082 | |
| GGKLIAHKKLDIGQY | 3596 | Q14517 | |
| YGKGVLSGEECKKQL | 146 | Q9NVI1 | |
| GTKERLFEGIIKGKY | 221 | O14936 | |
| IEVDGLSYKLEGLKK | 576 | P43146 | |
| LGKLYKIPELGGKDV | 1506 | Q8NEZ4 | |
| KLKGYQKRDVKLGGL | 646 | Q6NUN7 | |
| NEKLVKLESGLKVYG | 111 | Q16775 | |
| GGKIIHKIIDLGYAK | 156 | O15111 | |
| YKEALEAVLIKGKNG | 351 | P46020 | |
| LEKYKIGKVIGDGNF | 391 | Q8N568 | |
| KIQGIEEYKKGRGLE | 86 | Q9Y6G9 | |
| IIGLYKEKGKGLGFS | 586 | O15018 | |
| LGKNKITSEGGKYLA | 791 | Q9Y239 | |
| VKGLGIAIKELFAGK | 196 | Q8N8Q9 | |
| GEVYGLLGSVLTIKK | 1141 | P48552 | |
| LKEPDIEGKYLGKLG | 1256 | Q8IWU2 | |
| SGGELIERDGKKYKL | 251 | Q9P2T1 | |
| VYEEAGVKGKLGRLL | 66 | Q96G61 | |
| LAEGGGAKFKKYEEI | 81 | P49411 | |
| GSKAELVVGGKYKLV | 6 | Q8N752 | |
| LVVGGKYKLVRKIGS | 11 | Q8N752 | |
| KEKKDLGTLGYVLGI | 161 | Q96FE7 | |
| GLVLKDVKGTYEPGK | 656 | P49916 | |
| VGKVGGEVKLSISYK | 1501 | O00750 | |
| IKYKGEKDGALLVAV | 746 | Q9BX63 | |
| GGRIGIEEFAKYLKL | 376 | Q7L5N7 | |
| IDKILLEIGAKGKPY | 226 | Q01970 | |
| KVEKIGEGTYGVVYK | 6 | Q00526 | |
| GTGGALVLVLYDKIK | 291 | Q9H0C2 | |
| GIINVKGKGDLKTYF | 1061 | Q08462 | |
| YLSILTDPDGKGKEK | 4451 | P04114 | |
| FKRGVLKEYGVKVLG | 521 | P31327 | |
| KGEGVRYKAKLIGID | 36 | O75553 | |
| EIGFGKLETYIKLDK | 156 | Q00536 | |
| VAKGLGLSKAYVGQK | 2561 | P21333 | |
| GIKGAAYLKNKDGLV | 896 | Q8TF46 | |
| LAVLYEGIKVGKAKL | 36 | O15432 | |
| SGKGLVIYPKIGDKL | 46 | P98172 | |
| RGLGKTVLVKGLKYD | 176 | Q6P1S2 | |
| GAIIGFIKVGYKKLF | 91 | Q5SQI0 | |
| TLKDEIGKGSYGVVK | 166 | Q96RR4 | |
| KVEKIGEGTYGVVYK | 6 | P24941 | |
| KYVGAIEKLKLSEGK | 66 | O14713 | |
| LKKDAKYGLGFQIIG | 1096 | Q12923 | |
| KGSLLDFLKGETGKY | 346 | P12931 | |
| DLKSRGDKYGKLVGV | 196 | Q9HA77 | |
| KYKSEALGVGDVKLP | 181 | Q9UGI8 | |
| DFLKVIGKGNYGKVL | 36 | Q9HBY8 | |
| YLLSKDIKEVGLKGK | 706 | O15061 | |
| EKKLSGKLYLVDLAG | 221 | O60282 | |
| KIGQGYLIKDGKLIK | 286 | P39023 | |
| FIVGGKYKLVRKIGS | 11 | P48729 | |
| IVLGGYIIKKLKLGA | 486 | Q9H2Y9 | |
| ELQETLGKGTYGKVK | 56 | O60285 | |
| GGYIIKKFKLSLVGL | 346 | G3V0H7 | |
| LETLGKGTYGKVKKA | 56 | Q9H093 | |
| KEGGSLIYEKLGEKA | 131 | Q969I6 | |
| VVKGILKKDGPLGFY | 156 | Q9BXI2 | |
| LQEKITRGKYGEGAK | 31 | P78383 | |
| IESESKGIKGGKKVY | 2181 | P25054 | |
| KIEKIGEGTYGVVYK | 6 | P06493 | |
| AFLTVLKKGKPGEIY | 241 | O95455 | |
| QEGGEKHLKLVGKLY | 756 | Q8NI27 | |
| GLGITIAGYIGDKKL | 386 | O75970 | |
| EVVLKGDAKKLQLYG | 76 | Q9H9V4 | |
| YKGTLLGESLKLKVV | 116 | O75663 | |
| SLDVGGKKEYLIAGK | 101 | P16035 | |
| KKYIKLEEDGGCVIG | 386 | Q96JH7 | |
| IGVGKLLRVYDLGKK | 961 | Q15393 | |
| YGIVLLSGVKYKKGG | 166 | P48023 | |
| LSGVKYKKGGLVINE | 171 | P48023 | |
| YISLKELGGLSEGKK | 161 | Q8N4Q0 | |
| SDIKGLIKYLGEKVG | 286 | Q969S3 | |
| LIKYLGEKVGVGKIC | 291 | Q969S3 | |
| IGLGIKALQDKKYED | 276 | Q6PGP7 | |
| GGSKVLAKKELAYVP | 116 | Q9NRZ5 | |
| KIKKGGLNGVDIYSL | 541 | P01130 | |
| VYKIFGPGKKLGSLV | 496 | Q8IZF0 | |
| GIISPVGDAYKKKGL | 46 | Q9HAN9 |